WO2009058299A1 - P2x3 receptor antagonists for treatment of pain - Google Patents

P2x3 receptor antagonists for treatment of pain Download PDF

Info

Publication number
WO2009058299A1
WO2009058299A1 PCT/US2008/012271 US2008012271W WO2009058299A1 WO 2009058299 A1 WO2009058299 A1 WO 2009058299A1 US 2008012271 W US2008012271 W US 2008012271W WO 2009058299 A1 WO2009058299 A1 WO 2009058299A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
pyridin
aryl
ethyl
heterocyclyl
Prior art date
Application number
PCT/US2008/012271
Other languages
French (fr)
Inventor
Christopher S. Burgey
Diem N. Nguyen
Daniel V. Paone
Craig M. Potteiger
Joseph P. Vacca
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to EP08844889.9A priority Critical patent/EP2215048B1/en
Priority to US12/740,098 priority patent/US8461185B2/en
Priority to AU2008319309A priority patent/AU2008319309B2/en
Priority to ES08844889.9T priority patent/ES2553412T3/en
Priority to JP2010532049A priority patent/JP5552430B2/en
Priority to CA2703915A priority patent/CA2703915C/en
Publication of WO2009058299A1 publication Critical patent/WO2009058299A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the invention relates generally to compounds which act as modulators, e.g., antagonists of the P2X3 receptor, compositions and therapeutic uses thereof.
  • Purines acting via an extracellular purinoreceptor, have been implicated as having a variety of physiological and pathological roles. (See, Burnstock (1993) Drug Dev. Res. 28:195- 206.) Purinoreceptors (P2) have been generally categorized as either metabotropic nucleotide receptors or ionotropic receptors for extracellular nucleotides.
  • Metabotropic nucleotide receptors (usually designated P2 Y or P2 Y (n), where "n” is a subscript integer indicating subtype) are believed to differ from ionotropic receptors (usually designated P2X or P2X n ) in that they are based on a different fundamental means of transmembrane signal transduction: P2Y receptors operate through a G protein-coupled system, while P2X receptors are ligand-gated ion channels.
  • P2Xi cDNA was cloned from the smooth muscle of the rat vas deferens (Valera et al. (1994) Nature 371:516-519) and P2X 2 cDNA was cloned from PC12 cells (Brake et al. (1994) Nature 371 :519-523).
  • Five other P2X receptors have been found in cDNA libraries by virtue of their sequence similarity to P2X ⁇ and P2X 2 - P2X 3 : Lewis et al. (1995) Nature 377:432-435, Chen et al.
  • Purinergic receptors in particular, P2X receptors
  • P2X receptors are known to function as homomultimeric cation-permeable ion channels and, in some cases, as heteromeric channels consisting of two different P2X receptor subtypes (Lewis et al., Nature 377:432-435 (1995); Le et al., J. Neurosci. 18:7152-7159 (1998); Torres et al., MoI. Pharmacol. 54:989-993 (1998)).
  • the P2X 2 and P2X 3 subunits form functional channels when expressed alone, and can also form a functional heteromultimeric channel that has properties similar to currents seen in native sensory channels when co-expressed.
  • At least one pair of P2X receptor subtypes, P2X 2 and P2X 3 functions as a heteromeric channel in rat nodose ganglion neurons where it exhibits distinct pharmacological and electrophysiological properties (Lewis et al., supra (1995)).
  • Native P2X receptors are known to form rapidly activated, nonselective cationic channels upon activation by ATP.
  • the channels formed by P2X receptors generally have high Ca + permeability (P( Ca ) /P(Na) )•
  • the P2X 3 purinergic receptor is a ligand-gated cation channel that is selectively permeable to small cations.
  • Known ligands for P2X receptors include natural nucleotides, for example, ATP, UTP, UDP, or synthetic nucleotides, for example 2-methylthioATP.
  • ATP in addition to its function as an intracellular energy donor, is now recognized as an important neurotransmitter or cotransmitter, in both the central and peripheral nervous system (Ralevic, V., et al., Pharmacol. Rev., 50:413-492 (1998)). It is released from a variety of cell types, including nerve fibers, upon stimulation and produces diverse effects on many tissues by activation of specific membrane receptors including purinoreceptors (P2 receptor) (See Burnstock, G., Pharmacol. Rev., 24:509-581 (1972); Burnstock, G., Cell Membrane Receptor for Drugs and Hormones: A Multidisciplinary Approach, edited by R. W. Straub and L. Bolid.
  • P2 receptor purinoreceptors
  • ATP can stimulate sensory nerve endings resulting in intense pain and a pronounced increase in sensory nerve discharge.
  • ATP released from damaged cells can evoke pain by activating P2X 3 homomeric receptors, or P2X 2 /P2X 3 heteromeric receptors expressed on nociceptive nerve endings of sensory nerves. This is consistent with reports of the induction of pain by intradermally applied ATP in the human blister-base model; the identification of P2X 3 containing receptor on nociceptive neurons in the tooth pulp; and with reports that P2X antagonists are analgesic in animal models.
  • P2X 3 receptor gene disruption results in a diminished sensitivity to noxious chemical stimuli and reduced pain.
  • the nociceptive effects of exogenously administered ATP and P2X containing receptor agonists have also been demonstrated in laboratory animals. See Bland- Ward et al., Dr. J. Pharmacol. 122:366-371 (1997); Hamilton et al., Br. J. Phamacol. 126:326- 332 (1999).
  • the peripheral nociceptive actions of P2X activation and stimulation of spinal P2X containing receptor also contribute to nociception as indicated by the ability of intrathecally (i.t.) administered P2 receptor agonists to increase sensitivity to acute and persistent noxious stimuli in rodents.
  • P2X 3 containing receptors P2X 3 and/or P2X 2/3
  • P2X 3 and/or P2X 2/3 P2X 3 containing receptors
  • compounds which block or inhibit activation of P2X 3 receptors serve to block the pain stimulus.
  • receptor antagonists to compounds which normally activate the P2X 3 receptor and/or P2X 2 /P2X 3 heteromeric channels, such as ATP could successfully block the transmission of pain.
  • modulators of P2X receptors e.g., P2X 3 receptor may find use as analgesics.
  • compounds that block or inhibit activation of P2X 3 receptors also serve to treat genitourinary, gastrointestinal and respiratory diseases, conditions and disorders or receptor antagonists to compounds which normally activate the P2X 3 receptor and/or P2X 2 /P2X 3 heteromeric channels, such as ATP are useful for treatment of genitourinary, gastrointestinal and respiratory diseases, conditions and disorders.
  • P2X receptors have been studied in a number of neurons including sensory, sympathetic, parasympathetic, mesenteric, and central neurons (Zhong, et al. (1998) Br. J. Pharmacol. 125:771-781). These studies indicate that purinergic receptors play a role in affterent neurotransmission from the bladder, and that modulators of P2X receptors are potentially useful in the treatment of bladder disorders and other genitourinary diseases or conditions.
  • P2X3 receptors have been shown to be expressed in human colon, and are expressed at higher levels in inflamed colon, than in normal colon (Y. Yiangou et al, Neurokastroenterol Mot (2001) 13:365-69).
  • P2X3 receptors have also been implicated in detection of distension or intraluminal pressure in the intestine and initiation of reflex contractions (X. Bian et al. J. Physiol (2003) 551.1 :309-22), and have linked this to coilitis (G. Wynn et al., Am J. Physiol Gastrointest Liver Physiol (2004) 287:G647-57).
  • P2X 3 receptors also have been shown to be expressed in pulmonary neuroepithelial bodies (NEBs), implicating the receptor in pain transmission in the lung (Inge Brouns et al., Am J. Respir Cell MoI Biol (2000) 23:52061). Additionally, P2X 2 and P2X 3 receptors have been implicated in p ⁇ 2 detection in pulmonary NEBs (W. Rong et al., J Neurosci (2003) 23(36):11315-21).
  • the present invention aims to overcome some of the aforementioned drawbacks by providing novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.
  • the present invention relates to a novel P2X3 type receptor antagonists of structural formula I: or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein:
  • X and Y independently represent N, or CR 1 ;
  • A represents a five membered heterocyclyl selected from the group consisting of (CH2) n oxazolyl, (CH2) n isoxazolyl, (CH2) n dihydro-isoxazolyl, and (CH2) n oxadiazolyl;
  • Rl represents H, Ci -6 alkyl, halogen, (CH2) n CF3, C3.10 cycloalkyl, CN, (CH2) n OR2, (CH2)nC5-lO heterocyclyl, (CH2)nC6-10 aryU or Ci-6 alkoxy; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ci -6 alkyl, halogen, hydroxyl, (CH 2 )nCF 3 ,or CN;
  • R 2 represents H, Ci -6 alkyl
  • R3 represents CR2R4R5 ;
  • R2 and R3 can be combined with the nitrogen to which they are attached to form a C5.10 heterocyclyl optionally substituted with 1 to 3 groups of R a ;
  • R4 and R5 independently represent H, (CH2) n OR2, CHF2, (CH2) n C5-10 heterocyclyl, (CH2)nC6-10 aryl, C3.10 cycloalkyl, Ci-6 alkoxy, or Ci-6 alkyl; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of R a ;
  • R6 and R 7 independently represent hydrogen, Ci -6 alkyl, halogen, hydroxyl, (CH2)nCF3, C3-6 cycloalkyl, (CH2)nC5-lO heterocyclyl, or (CH2)nC6-10 aryl > said heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ci_6 alkyl, C5.10 heterocyclyl, halogen, (CH2) n OR 2 , - C(R2) 2 OR -C(O)R2, (CH2) n CF3,or CN;
  • R6 and R 7 can be combined with a carbon atom on the ring to form a 4 to 6 membered spirocycle
  • Ra represents Ci-6 alkyl, halogen, -OR2, hydroxyl, (CH2) n CF3, -O-, C3-6 cycloalkyl, C5.10 heterocyclyl, or C6-10 aryl > said heterocyclyl and aryl optionally substituted with 1 to 3 groups of C 1-6 alkyl, halogen, hydroxyl, (CH2) n CF3,or CN; and
  • n 0 to 4.
  • This invention also relates to compositions and methods for using the compounds disclosed herein. These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
  • the present invention relates to a novel P2X3 type receptor antagonists of structural formula I that are useful in treating pain and diseases associated with pain.
  • One embodiment of the present invention is realized when X and Y are not N at the same time and all other variables are as previously described.
  • Another embodiment of the present invention is realized when both X and Y are CH and all other variables are as previously described.
  • Another embodiment of the present invention is realized when X is N and Y is CH and all other variables are as previously described.
  • Another embodiment of the present invention is realized when A is isoxazolyl and all other variables are as previously described.
  • Another embodiment of the present invention is realized when A is oxazolyl and all other variables are as previously described.
  • Another embodiment of the present invention is realized when A is oxadiazolyl and all other variables are as previously described.
  • Another embodiment of the present invention is realized when A is linked to the phenyl ring through a nitrogen atom and all other variables are as previously described. Another embodiment of the present invention is realized when A is linked to the phenyl ring through a carbon atom and all other variables are as previously described.
  • R 2 is hydrogen and both of R 4 and R5 in R? are Cl -6 alkyl and all other variables are as previously described.
  • R 2 is hydrogen and one of R 4 and R5 in R3 is Cl -6 alkyl and the other is C5-10 heterocyclyl, said heterocylyl optionally substituted with 1 to 3 groups of R a and all other variables are as previously described.
  • Still another embodiment of the present invention is realized when R.6 and/or R7 are substituents on the carbon atoms of the ring.
  • a sub-embodiment of this invention is realized when one of R6 and R 7 is hydrogen and the other C5-10 heterocyclyl optionally substituted with
  • a sub-embodiment of formula II is realized when A is isoxazolyl. Another sub-embodiment of formula II is realized when A is dihydro-isoxazolyl. Another sub-embodiment of formula II is realized when A is oxazolyl. Another sub-embodiment of formula II is realized when A is oxadiazolyl. Another sub- embodiment of formula II is realized when X is nitrogen. Still another sub-embodiment of formula II is realized when X is CH.
  • Still another embodiment of the compound of formula II is realized when A is isoxazolyl, one of R 6 and R 7 is hydrogen and the other is C6-10 aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of R a , X is nitrogen, R3 is CHR 4 R5, and one of R 4 and R 5 is C 1-6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a .
  • a sub-embodiment of this invention is realized when said aryl and heterocyclyl in R 4 , R5, R6, and R 7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl.
  • A is dihydro-isoxazolyl
  • one of R6 and R 7 is hydrogen and the other is C6_io aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of R a
  • X is nitrogen
  • R3 is CHR 4 R ⁇
  • one of R4 and R.5 is Ci -6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a .
  • a sub-embodiment of this invention is realized when said aryl and heterocyclyl in R 4 , R5, R6 5 and R 7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl.
  • Still another sub-embodiment of the compound of formula II is realized when A is dihydro-isoxazolyl, and R6 and R7 are combined with a carbon atom on the ring they are attached to form a 4 to 6 membered spirocycle.
  • A is oxazolyl
  • one of R6 and R7 is hydrogen and the other is C ⁇ -io aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of R a
  • X is nitrogen
  • R3 is CHR 4 RS
  • one of R 4 and R5 is C 1-6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a .
  • a sub-embodiment of this invention is realized when said aryl and heterocyclyl in R 4 , R5 R6 ; and R 7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl.
  • Still another sub-embodiment of the compound of formula II is realized when A is dihydro-isoxazolyl, and R6 and R 7 are combined with a carbon atom on the ring they are attached to form a 4 to 6 membered spirocycle.
  • Still another embodiment of the compound of formula II is realized when A is isoxazolyl, one of R 6 and R7 is hydrogen and the other is C6-10 aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is CH, R3 is CHR 4 R5, and one of R 4 and R5 is C 1-6 alkyl and the other is C6-10 aryl, or C5-I0 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a .
  • a sub-embodiment of this invention is realized when said aryl and heterocyclyl in R 4 , R5, R6, and R7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl.
  • A is dihydro-isoxazolyl
  • one of R6 and R7 is hydrogen and the other is CO- 10 aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of R a
  • X is CH
  • R3 is CHR 4 R ⁇
  • one of R 4 and R 5 is Ci-6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a .
  • a sub-embodiment of this invention is realized when said aryl and heterocyclyl in R 4 , R5, R6 ?
  • R7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl.
  • A is oxazolyl
  • one of R6 and R 7 is hydrogen and the other is C ⁇ -io aryl > or C5-IO heterocyclyl optionally substituted with 1 to 3 groups of Ra
  • X is CH
  • R3 is CHR4R5
  • one of R4 and R5 is C 1-6 alkyl and the other is C6-10 aryl, or C5_io heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a .
  • a sub-embodiment of this invention is realized when said aryl and heterocyclyl in R4, R5 RO 5 and R?
  • any variable e.g. aryl, heterocycle, Rl, R ⁇ etc.
  • its definition on each occurrence is independent at every other occurrence.
  • combinations of substituents/or variables are permissible only if such combinations result in stable compounds.
  • R a is -O- and attached to a carbon it is referred to as a carbonyl group and when it is attached to a nitrogen (e.g., nitrogen atom on a pyridyl group) or sulfur atom it is referred to a N-oxide and sulfoxide group, respectively.
  • alkyl encompasses groups having the prefix “alk” such as, for example, alkoxy, alkanoyl, alkenyl, and alkynyl and means carbon chains which may be linear or branched or combinations thereof.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, and heptyl.
  • alkenyl refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond.
  • alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl.
  • alkenyl is C2-C6 alkenyl.
  • Preferred alkynyl are C2-C6 alkynyl.
  • alkenyl alkynyl and other like terms include carbon chains containing at least one unsaturated C-C bond.
  • fluoroalkyl refers to an alkyl substituent as described herin containing at least one flurine substituent.
  • cycloalkyl refers to a saturated hydrocarbon containing one ring having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • C 1-6 includes alkyls containing 6, 5, 4, 3, 2, or 1 carbon atoms
  • alkoxy as used herein, alone or in combination, includes an alkyl group connected to the oxy connecting atom.
  • alkoxy also includes alkyl ether groups, where the term 'alkyl' is defined above, and 'ether' means two alkyl groups with an oxygen atom between them.
  • suitable alkoxy groups include methoxy, ethoxy, n- propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, methoxymethane (also referred to as 'dimethyl ether'), and methoxyethane (also referred to as 'ethyl methyl ether').
  • aryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, napthyl, tetrahydronapthyl, indanyl, or biphenyl.
  • heterocycle, heterocyclyl, or heterocyclic represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocycle or heterocyclic includes heteroaryl moieties.
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyrid
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadia
  • the heterocyclic group is a heteroaryl group.
  • heteroaryl refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, between one and about three heteroatoms selected from the group consisting of N, 0, and S.
  • heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazoiyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, and isoxazolyl.
  • the heterocyclic group is fused to an aryl or heteroaryl group. Examples of such fused heterocycles include, without limitation, tetrahydroquinolinyl and dihydrobenzofuranyl.
  • heteroaryl represents a stable 5- to 7-membered monocyclic- or stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, such as piperidinyl, partially saturated, or unsaturated, such as pyridinyl, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heteroaryl groups include, but are not limited to, benzimidazole, benzisothiazole, benzisoxazole, benzofuran, benzothiazole, benzothiophene, benzotriazole, benzoxazole, carboline, cinnoline, furan, furazan, imidazole, indazole, indole, indolizine, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole,
  • heterocycloalkyls examples include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, imidazolinyl, pyrolidin-2-one, piperidin-2-one, and thiomorpholinyl.
  • heteroatom means O, S or N, selected on an independent basis.
  • a moiety that is substituted is one in which one or more hydrogens have been independently replaced with another chemical substituent.
  • substituted phenyls include 2-flurophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2,4fluor-3- propylphenyl.
  • substituted n-octyls include 2, 4 dimethyl-5- ethyl-octyl and 3-cyclopentyloctyl. Included within this definition are methylenes (-CH 2 -) substituted with oxygen to form carbonyl (-CO-).
  • Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-), nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, , alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups.
  • Preferred substituents, which are themselves not further substituted are:
  • Halogen refers to fluorine, chlorine, bromine and iodine.
  • the term “mammal” “mammalian” or “mammals” includes humans, as well as animals, such as dogs, cats, horses, pigs and cattle.
  • phrases "effective amount” or “therapeutically effective amount” mean a concentration of P2X receptor complex modulator sufficient to inhibit or enhance the effect of the P2X receptor complex.
  • Pain means the more or less localized sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.
  • pain There are many types of pain, including, but not limited to, lightning pains, phantom pains, shooting pains, acute pain, inflammatory pain, neuropathic pain, complex regional pain, neuralgia, neuropathy, tissue injury pain, and the like (Dorland's Illustrated Medical Dictionary, 28th Edition, W. B. Saunders
  • the goal of treatment of pain is to reduce the degree or severity of pain perceived by a treatment subject.
  • Treating" or “treatment of a disease state includes: 1) preventing the disease state, i.e. causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state, but does not yet experience or display symptoms of the disease state; 2) inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms; 3) or relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
  • the compounds of the present invention may contain one or more asymmetric centers and may thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers.
  • references to the compounds of structural formula I are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or in other synthetic manipulations.
  • the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines.
  • Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N, N -dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine
  • the compound of the present invention When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • compositions of the present invention comprise compounds of the invention (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents or adjuvants.
  • additional therapeutic agents can include, for example, i) opiate agonists or antagonists, ii) calcium channel antagonists, iii) 5HT receptor agonists or antagonists, iv) sodium channel antagonists, v) NMDA receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) NKl antagonists, viii) non-steroidal anti-inflammatory drugs ("NSAID”), ix) selective serotonin reuptake inhibitors ("SSRI”) and/or selective serotonin and norepinephrine reuptake inhibitors (“SSNRI”), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xiii) valproate, xiv) neurontin (gaba
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the present compounds and compositions are useful for the treatment of chronic, visceral, inflammatory and neuropathic pain syndromes. They are useful for the treatment of pain resulting from traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, small fiber neuropathy, and diabetic neuropathy.
  • the present compounds and compositions are also useful for the treatment of chronic lower back pain, phantom limb pain, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain and related neuralgias, and pain associated with cancer, chemotherapy, HIV and HIV treatment-induced neuropathy.
  • Compounds of this invention may also be utilized as local anesthetics.
  • Compounds of this invention are useful for the treatment of irritable bowel syndrome and related disorders, as well as Crohn's disease.
  • the instant compounds have clinical uses for the treatment of epilepsy and partial and generalized tonic seizures. They are also useful for neuroprotection under ischaemic conditions caused by stroke or neural trauma and for treating multiple sclerosis.
  • the present compounds are useful for the treatment of tachy-arrhythmias.
  • the instant compounds are useful for the treatment of neuropsychiatric disorders, including mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety disorders.
  • mood disorders such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders
  • bipolar disorders for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder
  • anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobia
  • mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats guinea pigs, or other bovine, ovine, equine, canine, feline, rodent such as mouse, species can be treated.
  • the method can also be practiced in other species, such as avian species (e.g., chickens).
  • a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents, such as norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors
  • SSRIs monoamine oxidase inhibitors
  • MAOIs monoamine oxidase inhibitors
  • RIMAs reversible inhibitors of monoamine oxidase
  • SNRJs noradrenaline reuptake inhibitors
  • ⁇ -adrenoreceptor antagonists atypical anti-depressants
  • benzodiazepines 5-HT 1A agonists or antagonists, especially 5-HT] A partial agonists, neurokinin- 1 receptor antagonists, corticotropin releasing factor (CRF) antagonists, and pharmaceutically acceptable salts thereof.
  • CRF corticotropin releasing factor
  • compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited conditions and disorders, as well as to prevent other conditions and disorders associated with calcium channel activity.
  • Creams, ointments, jellies, solutions, or suspensions containing the instant compounds can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention.
  • Dosage levels from about 0.01 mg/kg to about 140 mg/kg of body weight per day are useful in the treatment of inflammatory and neuropathic pain, or alternatively about 0.5 mg to about 7 g per patient per day.
  • inflammatory pain may be effectively treated by the administration of from about 0.0 lmg to about 75 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
  • Neuropathic pain may be effectively treated by the administration of from about 0.01 mg to about 125 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 5.5 g per patient per day.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration to humans may conveniently contain from about 0.5 mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may ary from about 5 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about 1 mg to about 1000 mg of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
  • the specific dose level for any particular patient will depend upon a variety of factors. Such patient-related factors include the age, body weight, general health, sex, and diet of the patient. Other factors include the time and route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
  • the compounds of the invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion.
  • the compounds of the invention, or pharmaceutically acceptable salts thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt.
  • the compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • oral liquid preparations such as suspensions, elixirs and solutions
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used; or in the case of oral solid preparations such as powders, capsules and tablets, carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included.
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included.
  • tablets and capsules represent the most advantageous oral dosage unit form in which solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • controlled release means and/or delivery devices may also be used in administering the instant compounds and compositions.
  • any convenient pharmaceutical media may be employed.
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used to form oral solid preparations such as powders, capsules and tablets.
  • tablets and capsules are advantageous oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet advantageously contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule advantageously containing from about 0.1 mg to about 500 mg of the active ingredient.
  • a tablet, cachet, or capsule conveniently contains 0.1 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg of the active ingredient taken one or two tablets, cachets, or capsules, once, twice, or three times daily.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions, hi all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage, and thus should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
  • compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, and dusting powder. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented of the invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid, such as, for example, where the mixture forms unit dose suppositories.
  • suitable carriers include cocoa butter and other materials commonly used in the art.
  • the suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.
  • the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
  • the instant compounds can be utilized in combination with one or more therapeutically active compounds.
  • inventive compounds can be advantageously used in combination with i) opiate agonists or antagonists, ii) other calcium channel antagonists, iii) 5HT receptor agonists or antagonists, including 5-HT 1A agonists or antagonists, and 5-HT 1 A partial agonists, iv) sodium channel antagonists, v) N-methyl-D- aspartate (NMDA) receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) neurokinin receptor 1 (NKl) antagonists, viii) non-steroidal anti-inflammatory drugs (NSAID), ix) selective serotonin reuptake inhibitors (SSRI) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xiii)
  • the present compounds can be prepared according to the procedures provided in the Examples.
  • the following Examples further describe, but do not limit, the scope of the invention.
  • NMR data is in the form of delta ( ⁇ ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz, 400 MHz or 500 MHz using the indicated solvent.
  • TMS tetramethylsilane
  • Conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. Broad; etc.
  • “Ar” signifies an aromatic signal.
  • the procedures described herein for synthesizing the compounds may include one or more steps of protecting group manipulations and of purification, such as, re-crystallization, distillation, column chromatography, flash chromatography, thin-layer chromatography (TLC), radial chromatography and high-pressure chromatography (HPLC).
  • the products can be characterized using various techniques well known in the chemical arts, including proton and carbon- 13 nuclear magnetic resonance ( 1 H and 13 C NMR), infrared and ultraviolet spectroscopy (IR and UV), X-ray crystallography, elemental analysis and HPLC and mass spectrometry (HPLC-MS).
  • Methods of protecting group manipulation, purification, structure identification and quantification are well known to one skilled in the art of chemical synthesis.
  • solvents are those which will at least partially dissolve one or all of the reactants and will not adversely interact with either the reactants or the product.
  • Suitable solvents are aromatic hydrocarbons (e.g, toluene, xylenes), halogenated solvents (e.g, methylene chloride, chloroform, carbontetrachloride, chlorobenzenes), ethers (e.g, diethyl ether, diisopropylether, tert-butyl methyl ether, diglyme, tetrahydrofuran, dioxane, anisole), nitriles (e.g, acetonitrile, propionitrile), ketones (e.g, 2-butanone, dithyl ketone, tert-butyl methyl ketone), alcohols (e.g, methanol, ethanol, n-propanol, iso-propanol, n-butanol, t-butanol
  • Suitable bases are, generally, alkali metal hydroxides, alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, and calcium hydroxide; alkali metal hydrides and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride; alkali metal amides such as lithium amide, sodium amide and potassium amide; alkali metal carbonates and alkaline earth metal carbonates such as lithium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, and cesium hydrogen carbonate; alkali metal alkoxides and alkaline earth metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and magnesium ethoxide; alkali metal alkyls such as methyllithium, n-butyllithium, sec-butyllithium, t-bultyl
  • compounds of this invention contain one or more stereocenters that may be prepared as single enantiomers or diastereomers, or as mixtures containing two or more enantiomers or diastereomers in any proportion.
  • the compounds of the present invention can be prepared readily according to the following Schemes and specific examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art but are not mentioned in greater detail.
  • the general procedures for making the compounds claimed in this invention can be readily understood and appreciated by one skilled in the art from viewing the following Schemes.
  • Isoxazoles can be prepared according to Scheme 1. Bromide 1 is oxidized to aldehyde 2_ which can be coupled with a range of aryl boronic acids under transition metal catalysis to give biaryl 3. Condensation with hydroxylamine gives oxime 4. Chlorination is followed by direct cyclization with a variety of alkynes to deliver isoxazole 5. Final deprotection and amide coupling under standard conditions gives the product 6.
  • isoxazoles can be prepared as depicted in Scheme 2, in which the synthetic steps have been reordered to allow for the production of the isoxazoles as the ultimate step.
  • Isoxazolines can be prepared according to Scheme 3. Chlorination of oxime 4 is followed by direct cyclization with a variety of alkenes to deliver isoxazoline 8. Final deprotection and amide coupling under standard conditions gives the product 9.
  • isoxazolines can be prepared as depicted in Scheme 4, in which the synthetic steps have been reordered to allow for the production of the isoxazoline as the ultimate step.
  • isoxazolines can be prepared as depicted in Scheme 5, in which the synthetic steps have been reordered to allow for the construction of the biaryl core as the ultimate step.
  • Amine intermediates of type J_8 can be prepared from one of several intermediates as shown in Scheme 6. This method utilizes diastereoselective Ellman sulfinimine addition chemistry to generate a pair of diastereomeric sulf namides. The diastereomers are separated by silica chromatography prior to HCl deprotection to give 18. Depending on the substrate either the R OT S Ellman reagent is utilized to favor the desired alpha methyl amino compound with the preferred stereo configuration shown.
  • the final product may be further modified, for example, by manipulation of substituents.
  • substituents may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art.
  • order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products.
  • the vessel was cooled to ambient temperature and the reaction was repressurized with carbon monoxide to 300 psi.
  • the vessel was heated to 90 0 C for an additional 4 h.
  • the vessel was cooled to ambient temperature and the remaining carbon monoxide was vented.
  • the mixture was concentrated to half of the volume.
  • Ethyl acetate (500 mL) and water (300 mL) were added.
  • the organic layer was isolated and the aqueous layer was extracted with ethyl acetate (2x).
  • the combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes ⁇ 70% hexanes/ ethyl acetate) gave the title compound (16 g). MS 170.0 (M+ 1).
  • Step C JV-
  • Step D JV-[CIi?)-! -(5-Fluoropyridin-2-yl ' )ethyll-2-methylpropane-2-sulfinamide
  • Step B 2-methyl-N- ⁇ ( IR)-I- [6-(trifluoromethyl)-3 -pyridinyl] ethyl ⁇ -2-propanesulfinamide
  • Step A Benzyl [(liS)-2-amino-l-methyl-2-thioxoethyl]carbamate
  • Step B Benzyl r ⁇ 5)-l-(4H-1.2.4-triazol-3-vnethyllcarbamate
  • Step C (15)-l-(4H-l,2,4-Triazol-3-vnethanamine
  • Step A tert-Butyl [(IR)-I -(5 -fluoropyridin-2-yOethyl] carbamate
  • Step B tert-Butyl [(l/?)-l-(5-fluoro-l-oxidopyridin-2-yl)ethyl]carbamate
  • Step C (li?yi-(5-Fluoro-l-oxidopyrindin-2-vPethanamine To a solution of tert-butyl [(li?)-l-(5-fluoro-l-oxidopyridin-2-yl)ethyl]carbamate
  • Step A tert-butyl ⁇ (li?)-l-[6-(trifluoromethyl)-3-pyridinyl1ethvUcarbamate
  • Step B tert-butyl ⁇ (li?)-l-
  • Step A tert-butyl
  • Step B (lRVl-C3-methyl-1.2,4-oxadiazol-5-yl)ethanamine
  • Step B tert-butyl methyl 5-bromoisophthalate
  • Step D tert-butyl 3-bromo-5-formylbenzoate
  • Step E t ⁇ rt-Butyl 3-bromo-5-r(E)-(hvdroxyimino)methyllbenzoate
  • hydroxylamine hydrochloride 44.0 g, 633 mmol
  • pyridine 103 mL, 1.27 mol
  • the reaction mixture was heated to 68 0 C. After 16 h, the mixture was concentrated. Saturated aqueous amonium chloride was added the mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated (125.0 g).
  • MS 243 M - tert-butyl
  • Step F tert-Butyl 3-bromo-5-[(5i?)-5-pyridin-2-yl-4,5-dihvdroisoxazol-3-yl]benzoate and tert- buryl 3-bromo-5-[(5SV5-pwidin-2-yl-4,5-dihvdroisoxazol-3-yl '
  • benzoate To a solution of tert-butyl 3-bromo-5-[(E)-
  • Step B tert-butyl 3-bromo-5-[(iTKhvdroxyirnino)methyl]benzoate
  • Step C tert-butyl 3-bromo-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl ' )ben2oate
  • Step B 3-( ' 5-Methylpyridin-2-yl)-5-
  • Step C N-rriieVl -(5-Fluoropyridin-2-vnethyl1-3-( ' 5-methylpyridin-2-vn-5-r(5 ⁇ )-5-pyridin-2-yl- 4,5-dihvdroisoxazol-3-yl]benzamide
  • Step A 3-(5-Methylpyridin-2-ylV5-f(5i?)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]benzoic acid
  • Step A and B N-r(li?Vl-( ' 5-Fluoropyridin-2-vnethyl1-3-( ' 5-methylpyridin-2-ylV5-r( ' 5igV5-pyridin-2-yl- 4.5-dihvdroisoxazol-3-yl]benzamide
  • Step A 3 -(5 -methyl-2- ⁇ yridinyl)-N- ⁇ ( 1 R)- 1 - ⁇ 1 -oxido-6-(trifluoromethvn-3 -pyridinyliethyl 1-5-
  • Step B 3-bromo-N-[ ⁇ i?Vl-( ' 5-fluoro-2-pyridmvnethvn-5-rr5 ⁇ -5-( ' 2-pyridinylV4.5-dihvdro-3- isoxazolyllbenzamide
  • Step C ⁇ f -rriigVl-r5-fluoro-2-pyridinvnethyl1-3-r(55)-5-( ' 2-pyridinylV4.5-dihvdro-3-isoxazolyl1- 5-C4.4.5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide
  • Step D 3-r5-chloro-2-pyridinvn-iV-f(li?Vl -(5-fluoro-2-pyridinvnethvn-5-r(5 ⁇ -5-r2-pyridinvn- 4.5-dihydro-3-isoxazolyl]benzamide
  • Step A methyl 3-(5-methyl-2-pyridinyl)-5-vinylbenzoate
  • Step B 3-(5-methyl-2-pyridinylV5-vinylbenzoic acid
  • Step C N-F(Ii?)-! -(5-fluoro-2-pyridinv ⁇ ethyll-3-(5-methyl-2-pyridinyl ' )-5-vinylbenzamide
  • N,N-dimethylformamide 20 mL
  • Step D N-Fd ⁇ )-I -( ' 5-fluoro-2-pyridinyl ' )ethyl1-3-formyl-5-( ' 5-methyl-2-pyridiny ⁇ benzamide
  • N-[(li?)-l-(5-fluoro-2-pyridinyl)ethyl]-3-(5-methyl-2- pyridinyl)-5-vinylbenzamide (1.14 g, 3.15 mmol) in tetrahydrofuran (11 mL) and water (11 mL) were added sodium periodate (2.0 g, 9.45 mmol) and osmium tetroxide (2.5% in tert-butanol, 2.0 mL, 0.157 mmol).
  • Step E N- ⁇ (IRY ⁇ -r5-fluoro-2-pyridinyl)ethyll-3-[( ' E)-rhvdroxyimino)methyl1-5-( ' 5-methyl-2- pyridinv ⁇ benzamide
  • Step F 3-( ⁇ [(lJ?)-l-(5-fluoro-2-pyridinyl)ethyl1aminolcarbony ⁇ -N-hydroxy-5-(5-methyl-2- pyridinyPbenzenecarboximidoyl chloride
  • Step G N-r(li?Vl-r5-fluoro-2-pyridinvnethyll-3-r5-hvdroxy-5-(2-pyridinylV4.5-dihvdro-3- isoxazolyll -5 -(5 -methyl -2 -pyridinvObenzamide
  • reaction mixture was sequentially added (1 equivalent, ⁇ 5 mL, per portion) to a solution of 3-( ⁇ [(li?)-l-(5-fluoro-2-pyridinyl)ethyl]amino ⁇ carbonyl)-N-hydroxy-5- (5-methyl-2-pyridinyl)benzenecarboximidoyl chloride (0.765 g, 1.85 mmol) in tetrahydrofuran (4 mL) at -78 °C. After addition of 5 equivalents (-25 mL), the reaction mixture was warmed to 0 °C. Saturated aqueous ammonium chloride was added. The mixture was extracted with dichloromethane (3x).
  • Step B 3-(5-methylpyridin-2-ylV5- ⁇ ,3-oxazol-2-y0benzoic acid
  • Step C 3-f5-rnethylpyridin-2-vn-5-fl.3-oxazol-2-vn-.V- ( nRVl-ri-oxido-6- ftrifluoromethyl)pyridin-3-yl1ethyl ⁇ benzamide
  • Step A tert-butyl 4'-methyl-5-(5-oxa-6-azaspiro[ ' 3.4 '
  • tert-butyl 3-bromo-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7- yl)benzoate (1.36 g, 3.71 mmol) in THF (8 mL) and water (8 mL) were added (4- methylphenyl)boronic acid (1.01 g, 7.43 mmol), dichloro[l,l'- bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (82 mg, 0.11 mmol) and cesium carbonate (3.63 g, 11.1 mmol).
  • the mixture was heated to 120 0 C in a microwave reactor for 10 min.
  • the mixture was cooled to ambient temperature and saturated aqueous NaHCO 3 was added and the mixture was extracted with ethyl acetate (3x).
  • the combined organic extracts were washed with water (2x), brine, dried over sodium sulfate, filtered and concentrated.
  • Step B 4'-methyl-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl)biphenyl-3-carboxylic acid
  • Step C 4'-Methyl-5-r5-oxa-6-azaspiror3.41oct-6-en-7-vn-iV-rri ⁇ -l-(4H-1.2.4-triazol-3- yllethyllbiphenyl-3-carboxamide
  • Step A tert-buty ⁇ 3-(5-methylpyridin-2-yl)-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl ' )berizoate
  • tert-butyl 3-bromo-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7- yl)benzoate (1.42 g, 3.88 mmol)
  • bis(tri-tert-butylphosphine)palladium(0) 59.0 mg, 0.12 mmol
  • dioxane 20 mL
  • Step B 3-(5-methylpyridin-2-yl)-5-( ' 5-oxa-6-azaspiro[3.4]oct-6-en-7-v ⁇ benzoic acid
  • Step C .V-rO-gy 1 -f3.5-difluoropyrid ⁇ n-2-vnethvn-3-f 5-methylpyrid ⁇ n-2-ylV5-(5-oxa-6- azaspuO[3.4]oct-6-en-7-yl * )benzamide
  • mice After overnight food-deprivation, male Sprague-Dawley rats are slightly anesthetized (isoflurane) and injected with 1% acetic acid into the colon (1.5 ml) using a cannula of 5 cm in length. After a recovery period of 75 minutes, rats are again slightly anesthetized (isoflurane) and a latex balloon of 1.5 cm in length tightly attached to a catheter is inserted via the anus into the descending colon and rectum. Anesthesia is then immediately discontinued. 15 minutes later, the test substance is administered p.o. 60 minutes after administration, the balloon is filled with 1.2 ml of water and the number of abdominal contractions is counted for 10 minutes. 10 rats are studied per group. The test is performed blind.
  • test substance will be evaluated at 3 doses, and compared with the vehicle group. Rats will be euthanized at the end of the experiments by exposure to a mixture of O 2 /CO 2 (20%/80%) followed by CO 2 . Data will be analyzed by comparing treated groups with vehicle control using Mann Whitney U tests.
  • spinal nerve ligation For the spinal nerve ligation (SNL) procedure, male Sprague Dawley rats (100-200 g; Harlan) are anesthetized using isoflurane (1-5%; inhalation). Using aseptic technique, a dorsal midline incision is made from approximately spinal nerve L3 to S2. A combination of sharp and blunt dissection is used to expose the L6/S1 posterior interarticular process. The L6 transverse process is visualized and removed, and the L4 and L5 spinal nerves are exposed distal to their emergence from the intervertebral foramina. The L5 nerve is then tightly ligated with 6-0 silk suture. The muscle is closed with 4-0 absorbable suture and the skin is closed with wound clips.
  • SNL spinal nerve ligation
  • Postoperative monitoring is carried out to assure that animals are exposed to the least amount of pain as possible. Animals are housed in pairs on bedding and are monitored (2x) daily for three days post-operatively by Laboratory Animal Resource staff and then daily by investigator for any signs of possible distress.
  • Behavioral testing Prior to surgery, rats are tested for pre-surgery mechanical hind paw withdrawal thresholds by applying a series of calibrated von Frey filaments (0.25 - 15 g) to the left hind paw and determining the median withdrawal threshold using the Dixon "up-down" method (Chaplan et al., J Neurosci Meth 53:55, 1994). Rats are placed in individual plastic chambers on an elevated mesh galvanized steel platform and allowed to acclimate for 60 min.
  • CFA Complete Freunds adjuvant
  • mice Male Sprague Dawley rats (300-400 g; Charles River) receive an intradermal injection of CFA (200 ul, 0.5 mg/ml) into the plantar aspect of the left hind paw and are subsequently returned to their cages where they are maintained on soft bedding. 72 hrs following CFA injection rats are tested for post-CFA mechanical hind paw withdrawal thresholds by wrapping the rat in a towel and placing the hind paw (either left or right) in a modified Randall-Sellito paw pinch apparatus (Stoelting, Wood Dale, IL).
  • CFA 200 ul, 0.5 mg/ml
  • 72 hrs following CFA injection rats are tested for post-CFA mechanical hind paw withdrawal thresholds by wrapping the rat in a towel and placing the hind paw (either left or right) in a modified Randall-Sellito paw pinch apparatus (Stoelting, Wood Dale, IL).
  • a plastic bar attached to a lever is placed on the dorsum of the hind paw, and an increasing force is applied to the hind paw until the rat vocalizes or pulls its hind paw away from the bar.
  • the rat's hind paw withdrawal threshold is recorded at that point.
  • the mechanical stimulus is applied to each hind paw 2 times, and the average post- CFA mechanical hind paw withdrawal thresholds are determined for both the left and right hind paw.
  • rats receive test compound, vehicle, or the positive comparator naproxen (30 mg/kg, p.o.), and effects of compounds on withdrawal thresholds for the inflamed (CFA) hind paw are determined.
  • Efficacy in the CFA model is evaluated by determining the % reversal of mechanical hypersensitivity using the formula:
  • the intravesical pressure was measured using a pressure transducer, and signal was recorded using a multiple channel data acquisition system (Power lab, AD Instruments, Biopac systems, Colorado Springs, CO) at a sampling rate of 10 Hz. After confirming stable inter-micturtion interval and micturition pressure by intravesical infusion of saline, the drugs were administered intravenously (0.25 ml/kg). Intermicturition interval (functional bladder capacity) and micturition pressure (maximum intravesical pressure) were obtained from micturitions prior to dosing (baseline) and between 5 to 30 min after dosing using Chart program (v5.5.4, AD Instruments), and calculated the ratio to baseline.
  • Intermicturition interval functional bladder capacity
  • micturition pressure maximum intravesical pressure
  • mice Female Sprague-Dawley rats weighed 250-350 g were housed in a temperature- and light (12-h light/dark cycle)-controlled room, and were allowed access to food and water ad libitum. The animals were anesthetized with urethane (1.0 g/kg, i.p.). Supplemental urethane was given if necessarily. A lower abdominal midline incision was made to expose the bladder, and a polyethylene catheter (PE-50) was inserted into the bladder dome for recording the intravesical pressure and intravesical infusion at the rate of 0.05 ml/min.
  • PE-50 polyethylene catheter
  • the intravesical pressure was measured using a pressure transducer, and signal was recorded using a multiple channel data acquisition system (Power lab, AD Instruments, Biopac systems, Colorado Springs, CO) at a sampling rate of 10 Hz. After confirming stable inter-micturtion interval and micturition pressure by intravesical infusion of saline, 0.25% of acetic acid-saline solution was infused at the same infusion rate. After 30-60 min, drugs were intravenously infused using infusion pumps at a rate of 10 ⁇ l/min.
  • Intermicturition interval functional bladder capacity
  • micturition pressure maximal intravesical pressure
  • Human P2X$ and P2X2 /3 Stable Cell Line - Human P2X 3 receptor cDNA (Accession number NM_002559) was subcloned as a 5'XhoI and 3'HindIII fragment into the expression vector pcDNA5/FRT (Invitrogen).
  • Human P2X 2 receptor cDNA (Accession number NM l 74873) was subcloned as a 5 ⁇ coRI and 3'NotI fragment into the expression vector pIRESneo2 (BD Biosciences Clontech).
  • the human P2X 3 expression construct was transfected using Lipofectamine 2000 (Invitrogen) into Flp-in - 293 cells (Invitrogen) according to the manufacturer's directions.
  • the stable human P2X 3 cell line was co-transfected with the human P2X 2 expression construct using Lipofectamine 2000 as above and co-transfected cells selected using 100 mg/ml hygromycin and 1 mg/ml G418.
  • the stable P2X 3 cell line was propagated in DMEM, 10% FBS, 100 ⁇ g/ml hygromycin, and 100 units/ml penicillin and 100 ⁇ g/ml streptomycin, and maintained at 37 ° and 95% humidity.
  • the stable P2X 2/3 cell line was propagated as above with the addition of 500 ⁇ g/ml G418.
  • Intracellular Calcium Measurement to Assess Antagonist Affinity A fluorescent imaging plate reader (FLIPR; Molecular Devices) was used to monitor intracellular calcium levels using the calcium-chelating dye Fluo-4 (Molecular Probes). The excitation and emission wavelengths used to monitor fluorescence were 488 run and 530 nm, respectively. Cells expressing either human P2X 3 or human P2X 2/3 were plated at a density of 20,000 cells/well (20 ⁇ l/well) in 384- well black- walled plates approximately 20 hours before beginning the assay.
  • FLIPR fluorescent imaging plate reader
  • the bath solution contained 150 mM NaCl, 4 mM KCl, 2 mM CaCl 2 , 1.2 mM
  • the control P2X 3 current amplitude (Ip 2 ⁇ 3 -( Co n t r o i)) was taken as an average of the peak current amplitude from the last two agonist additions prior to incubation with an antagonist.
  • the peak P2X 3 current amplitude in the presence of an antagonist (Ip 2 X 3- (CIrUg)) was used to calculate the inhibitory effect at each concentration of the antagonist according to the following equation:
  • % inhibition of P2X 3 100*(Ip 2 ⁇ 3- ( CO ntrol)-Ip2X3-(drug))/Ip2X3-(controI)
  • concentration of an antagonist was tested on at least two independent cells.
  • concentration of drug required to inhibit P2X 3 current by 50% was determined by fitting of the Hill equation to the averaged % inhibition data at each concentration:
  • the compounds below have an IC 50 of 200 nM or less in the "Intracellular Calcium Measurement to Assess Antagonist Affinity" assay:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

Description

TITLE OF THE INVENTION
P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
FIELD OF THE INVENTION
The invention relates generally to compounds which act as modulators, e.g., antagonists of the P2X3 receptor, compositions and therapeutic uses thereof.
BACKGROUND OF THE INVENTION
Purines, acting via an extracellular purinoreceptor, have been implicated as having a variety of physiological and pathological roles. (See, Burnstock (1993) Drug Dev. Res. 28:195- 206.) Purinoreceptors (P2) have been generally categorized as either metabotropic nucleotide receptors or ionotropic receptors for extracellular nucleotides. Metabotropic nucleotide receptors (usually designated P2 Y or P2 Y(n), where "n" is a subscript integer indicating subtype) are believed to differ from ionotropic receptors (usually designated P2X or P2Xn) in that they are based on a different fundamental means of transmembrane signal transduction: P2Y receptors operate through a G protein-coupled system, while P2X receptors are ligand-gated ion channels.
At least seven P2X receptors, and the cDNA sequences encoding them, have been identified to date. P2Xi cDNA was cloned from the smooth muscle of the rat vas deferens (Valera et al. (1994) Nature 371:516-519) and P2X2 cDNA was cloned from PC12 cells (Brake et al. (1994) Nature 371 :519-523). Five other P2X receptors have been found in cDNA libraries by virtue of their sequence similarity to P2X} and P2X2 - P2X3 : Lewis et al. (1995) Nature 377:432-435, Chen et al. (1995) Nature 377:428-431; P2X4 : Buell et al. (1996) EMBO J. 15:55- 62, Seguela et al. (1996) J. Neurosci. 16:448-455, Bo et al. (1995) FEBS Lett. 375:129-133, Soto et al. (1996) Proc. Natl. Acad. Sci. USA 93:3684-3688, Wang et al. (1996) Biochem. Biophys. Res. Commun.220: 196-202; P2X5 : Collo et al. (1996) J. Neurosci. 16:2495-2507, Garcia- Guzman et al. (1996) FEBS Lett. 388:123-127; P2X6 : Collo et al. (1996), supra, Soto et al. (1996) Biochem. Biophys. Res. Cornmun. 223:456-460; P2X7 : Surprenant et al. (1996) Science 272:735-738). For a comparison of the amino acid sequences of rat P2X receptor see Buell et al. (1996) Eur. J. Neurosci. 8:2221-2228. Purinergic receptors, in particular, P2X receptors, are known to function as homomultimeric cation-permeable ion channels and, in some cases, as heteromeric channels consisting of two different P2X receptor subtypes (Lewis et al., Nature 377:432-435 (1995); Le et al., J. Neurosci. 18:7152-7159 (1998); Torres et al., MoI. Pharmacol. 54:989-993 (1998)). The P2X2 and P2X3 subunits form functional channels when expressed alone, and can also form a functional heteromultimeric channel that has properties similar to currents seen in native sensory channels when co-expressed. At least one pair of P2X receptor subtypes, P2X2 and P2X3, functions as a heteromeric channel in rat nodose ganglion neurons where it exhibits distinct pharmacological and electrophysiological properties (Lewis et al., supra (1995)).
Native P2X receptors are known to form rapidly activated, nonselective cationic channels upon activation by ATP. The channels formed by P2X receptors generally have high Ca + permeability (P(Ca) /P(Na) )• With respect to individual receptors, the P2X3 purinergic receptor is a ligand-gated cation channel that is selectively permeable to small cations. Known ligands for P2X receptors include natural nucleotides, for example, ATP, UTP, UDP, or synthetic nucleotides, for example 2-methylthioATP. ATP, in addition to its function as an intracellular energy donor, is now recognized as an important neurotransmitter or cotransmitter, in both the central and peripheral nervous system (Ralevic, V., et al., Pharmacol. Rev., 50:413-492 (1998)). It is released from a variety of cell types, including nerve fibers, upon stimulation and produces diverse effects on many tissues by activation of specific membrane receptors including purinoreceptors (P2 receptor) (See Burnstock, G., Pharmacol. Rev., 24:509-581 (1972); Burnstock, G., Cell Membrane Receptor for Drugs and Hormones: A Multidisciplinary Approach, edited by R. W. Straub and L. Bolid. New York: Raven, 1978, p.107-118). With respect to the P2X purinergic receptor, data suggest that ATP is capable of activating P2X3 homomeric receptors and P2X2 /P2X3 heteromeric receptors where it functions as an excitatory neurotransmitter in the spinal cord dorsal horn and in primary afferents from sensory ganglia. In vitro, co-expression of P2X2 and P2X3 receptor subunits is necessary to produce ATP-gated currents with the properties seen in some sensory neurons. See, Lewis, et al. (1995) Nature 377:432-435.
ATP, and to a lesser extent, adenosine, can stimulate sensory nerve endings resulting in intense pain and a pronounced increase in sensory nerve discharge. According to available data, ATP released from damaged cells can evoke pain by activating P2X3 homomeric receptors, or P2X2/P2X3 heteromeric receptors expressed on nociceptive nerve endings of sensory nerves. This is consistent with reports of the induction of pain by intradermally applied ATP in the human blister-base model; the identification of P2X3 containing receptor on nociceptive neurons in the tooth pulp; and with reports that P2X antagonists are analgesic in animal models. To date, research data suggests that the mechanism whereby ATP-induced activation of the P2X purinergic receptors on dorsal root ganglion nerve terminals in the spinal cord and on neurons in the brain results in pain sensation is by the stimulation of the release of glutamate, a key neurotransmitter involved in nociceptive signaling.
It has also been recently demonstrated that P2X3 receptor gene disruption results in a diminished sensitivity to noxious chemical stimuli and reduced pain. The nociceptive effects of exogenously administered ATP and P2X containing receptor agonists have also been demonstrated in laboratory animals. See Bland- Ward et al., Dr. J. Pharmacol. 122:366-371 (1997); Hamilton et al., Br. J. Phamacol. 126:326- 332 (1999). The peripheral nociceptive actions of P2X activation and stimulation of spinal P2X containing receptor also contribute to nociception as indicated by the ability of intrathecally (i.t.) administered P2 receptor agonists to increase sensitivity to acute and persistent noxious stimuli in rodents. See Driessen et al., Brain Res. 666:182-188 (1994); Tsuda et al., Br. J. Pharmacol. 127:449-4S6 (1999); Tsuda et al., Br. J. Pharmacol. 128:1497- 1504 (1999). A selective P2 receptor-mediated increase in ectopic neuronal excitability that is localized to damaged sensory afferents has also been recently reported in rats following chronic constriction nerve injury. See Chen et al., NeuroReport 10:2779-2782 (1999). This role in pain transmission is consistent with the observation that the rat P2X3 receptor expression is found primarily in a subset of neurons of the sensory ganglia, which are involved in pain transmission. See Chen et al., Nature 377:428-430 (1995); Vulchanova et al., Neuropharmacol. 36:1229-1242 (1997). See also US20080004442, US200700409609, WO2007041087, WO2006119504, WO200112627, WO2007001973 and WO2007010553.
Taken together, the functional and immunohistochemical localization of P2X3 containing receptors (P2X3 and/or P2X2/3) on sensory nerves indicates that these P2X receptors may have a primary role in mediating the nociceptive effects of ATP. Thus, compounds which block or inhibit activation of P2X3 receptors serve to block the pain stimulus. More, receptor antagonists to compounds which normally activate the P2X3 receptor and/or P2X2/P2X3 heteromeric channels, such as ATP, could successfully block the transmission of pain. Indeed, modulators of P2X receptors, e.g., P2X3 receptor may find use as analgesics.
Additionally, compounds that block or inhibit activation of P2X3 receptors also serve to treat genitourinary, gastrointestinal and respiratory diseases, conditions and disorders or receptor antagonists to compounds which normally activate the P2X3 receptor and/or P2X2/P2X3 heteromeric channels, such as ATP are useful for treatment of genitourinary, gastrointestinal and respiratory diseases, conditions and disorders.
Burnstock (1999) J. Anatomy 194:335-342; and Ferguson et al. (1997) J. Physiol. 505:503-511 disclose that P2X receptor subunits have been found on afferents in rodent and human bladder urothelium. There data suggests that ATP may be released from epithelial/endothelial cells of the urinary bladder or other hollow organs as a result of distention. ATP released in this manner may serve a role in conveying information to sensory neurons located in subepithelial components, e.g., suburothelial lamina propria (Namasibayam, et al. (1999) BJU Intl. 84:854-860). P2X receptors have been studied in a number of neurons including sensory, sympathetic, parasympathetic, mesenteric, and central neurons (Zhong, et al. (1998) Br. J. Pharmacol. 125:771-781). These studies indicate that purinergic receptors play a role in affterent neurotransmission from the bladder, and that modulators of P2X receptors are potentially useful in the treatment of bladder disorders and other genitourinary diseases or conditions. P2X3 receptors have been shown to be expressed in human colon, and are expressed at higher levels in inflamed colon, than in normal colon (Y. Yiangou et al, Neurokastroenterol Mot (2001) 13:365-69). P2X3 receptors have also been implicated in detection of distension or intraluminal pressure in the intestine and initiation of reflex contractions (X. Bian et al. J. Physiol (2003) 551.1 :309-22), and have linked this to coilitis (G. Wynn et al., Am J. Physiol Gastrointest Liver Physiol (2004) 287:G647-57).
P2X3 receptors also have been shown to be expressed in pulmonary neuroepithelial bodies (NEBs), implicating the receptor in pain transmission in the lung (Inge Brouns et al., Am J. Respir Cell MoI Biol (2000) 23:52061). Additionally, P2X2 and P2X3 receptors have been implicated in pθ2 detection in pulmonary NEBs (W. Rong et al., J Neurosci (2003) 23(36):11315-21).
However, the utility of available purinergic ligands to evaluate the role of individual P2 receptor subtypes in mammalian physiology has been complicated by the susceptibility of P2 receptor agonists to undergo enzymatic degradation. As well, the study of the role of an individual P2X receptor is hampered by the lack of receptor subtype-specific agonists and antagonists.
Consequently, the state of the art begs an inquiry into methods and/or compounds which will provide the ability to regulate or control the P2X receptors, for example, P2X3, because control of such receptors will provide the ability to minimize pain in patients in need of such treatment. In addition, for both research and therapeutic purposes there is a need in the art for specific agonists and antagonists for each P2X receptor subtype and, in particular, agents that will be effective in vivo, as well as for methods for identifying purinoreceptor-specific agonist and antagonist compounds.
The present invention aims to overcome some of the aforementioned drawbacks by providing novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.
SUMMARY OF THE INVENTION The present invention relates to a novel P2X3 type receptor antagonists of structural formula I:
Figure imgf000006_0001
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein:
X and Y independently represent N, or CR1;
A represents a five membered heterocyclyl selected from the group consisting of (CH2)noxazolyl, (CH2)nisoxazolyl, (CH2)ndihydro-isoxazolyl, and (CH2)noxadiazolyl;
Rl represents H, Ci -6 alkyl, halogen, (CH2)nCF3, C3.10 cycloalkyl, CN, (CH2)nOR2, (CH2)nC5-lO heterocyclyl, (CH2)nC6-10 aryU or Ci-6 alkoxy; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ci -6 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN;
R2 represents H, Ci -6 alkyl;
R3 represents CR2R4R5;
or R2 and R3 can be combined with the nitrogen to which they are attached to form a C5.10 heterocyclyl optionally substituted with 1 to 3 groups of Ra;
R4 and R5 independently represent H, (CH2)nOR2, CHF2, (CH2)nC5-10 heterocyclyl, (CH2)nC6-10 aryl, C3.10 cycloalkyl, Ci-6 alkoxy, or Ci-6 alkyl; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ra;
R6 and R7 independently represent hydrogen, Ci -6 alkyl, halogen, hydroxyl, (CH2)nCF3, C3-6 cycloalkyl, (CH2)nC5-lO heterocyclyl, or (CH2)nC6-10 aryl> said heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ci_6 alkyl, C5.10 heterocyclyl, halogen, (CH2)nOR2, - C(R2)2OR -C(O)R2, (CH2)nCF3,or CN;
or R6 and R7 can be combined with a carbon atom on the ring to form a 4 to 6 membered spirocycle; Ra represents Ci-6 alkyl, halogen, -OR2, hydroxyl, (CH2)nCF3, -O-, C3-6 cycloalkyl, C5.10 heterocyclyl, or C6-10 aryl> said heterocyclyl and aryl optionally substituted with 1 to 3 groups of C 1-6 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN; and
n represents 0 to 4.
This invention also relates to compositions and methods for using the compounds disclosed herein. These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a novel P2X3 type receptor antagonists of structural formula I that are useful in treating pain and diseases associated with pain.
One embodiment of the present invention is realized when X and Y are not N at the same time and all other variables are as previously described.
Another embodiment of the present invention is realized when both X and Y are CH and all other variables are as previously described.
Another embodiment of the present invention is realized when X is N and Y is CH and all other variables are as previously described. Another embodiment of the present invention is realized when A is isoxazolyl and all other variables are as previously described.
Another embodiment of the present invention is realized when A is dihydro- isoxazolyl and all other variables are as previously described.
Another embodiment of the present invention is realized when A is oxazolyl and all other variables are as previously described.
Another embodiment of the present invention is realized when A is oxadiazolyl and all other variables are as previously described.
Another embodiment of the present invention is realized when A is linked to the phenyl ring through a nitrogen atom and all other variables are as previously described. Another embodiment of the present invention is realized when A is linked to the phenyl ring through a carbon atom and all other variables are as previously described.
Another embodiment of the present invention is realized when the R2 is hydrogen and both of R4 and R5 in R? are Cl -6 alkyl and all other variables are as previously described.
Another embodiment of the present invention is realized when the R2 is hydrogen and one of R4 and R5 in R3 is Cl -6 alkyl and the other is C5-10 heterocyclyl, said heterocylyl optionally substituted with 1 to 3 groups of Ra and all other variables are as previously described. Still another embodiment of the present invention is realized when R.6 and/or R7 are substituents on the carbon atoms of the ring. A sub-embodiment of this invention is realized when one of R6 and R7 is hydrogen and the other C5-10 heterocyclyl optionally substituted with
1 to 3 groups of Ra.
Yet another embodiment of the present invention is realized when one of R6 and R7 is a substituent on the nitrogen atom of the ring and all other variables are as previously described.
Another embodiment of the present invention is realized with a compound of formula II:
Figure imgf000008_0001
II or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein X, A, Rl, R3, R6; and R? are as previously described. A sub-embodiment of formula II is realized when A is isoxazolyl. Another sub-embodiment of formula II is realized when A is dihydro-isoxazolyl. Another sub-embodiment of formula II is realized when A is oxazolyl. Another sub-embodiment of formula II is realized when A is oxadiazolyl. Another sub- embodiment of formula II is realized when X is nitrogen. Still another sub-embodiment of formula II is realized when X is CH.
Still another embodiment of the compound of formula II is realized when A is isoxazolyl, one of R6 and R7 is hydrogen and the other is C6-10 aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is nitrogen, R3 is CHR4R5, and one of R4 and R5 is C 1-6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A sub-embodiment of this invention is realized when said aryl and heterocyclyl in R4, R5, R6, and R7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl.
Yet another sub-embodiment of the compound of formula II is realized when A is isoxazolyl, and R6 and R7 are combined with a carbon atom on the ring they are attached to form a 4 to 6 membered spirocycle. Another embodiment of the compound of formula II is realized when A is dihydro-isoxazolyl, one of R6 and R7 is hydrogen and the other is C6_io aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is nitrogen, R3 is CHR4R^, and one of R4 and R.5 is Ci -6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A sub-embodiment of this invention is realized when said aryl and heterocyclyl in R4, R5, R65 and R7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl. Still another sub-embodiment of the compound of formula II is realized when A is dihydro-isoxazolyl, and R6 and R7 are combined with a carbon atom on the ring they are attached to form a 4 to 6 membered spirocycle. Another embodiment of the compound of formula II is realized when A is oxazolyl, one of R6 and R7 is hydrogen and the other is Cό-io aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is nitrogen, R3 is CHR4RS, and one of R4 and R5 is C 1-6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A sub-embodiment of this invention is realized when said aryl and heterocyclyl in R4, R5 R6; and R7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl.
Still another sub-embodiment of the compound of formula II is realized when A is dihydro-isoxazolyl, and R6 and R7 are combined with a carbon atom on the ring they are attached to form a 4 to 6 membered spirocycle.
Still another embodiment of the compound of formula II is realized when A is isoxazolyl, one of R6 and R7 is hydrogen and the other is C6-10 aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is CH, R3 is CHR4R5, and one of R4 and R5 is C 1-6 alkyl and the other is C6-10 aryl, or C5-I0 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A sub-embodiment of this invention is realized when said aryl and heterocyclyl in R4, R5, R6, and R7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl. Another embodiment of the compound of formula II is realized when A is dihydro-isoxazolyl, one of R6 and R7 is hydrogen and the other is CO- 10 aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is CH, R3 is CHR4R^, and one of R4 and R5 is Ci-6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A sub-embodiment of this invention is realized when said aryl and heterocyclyl in R4, R5, R6? and R7 are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl. Another embodiment of the compound of formula II is realized when A is oxazolyl, one of R6 and R7 is hydrogen and the other is Cό-io aryl> or C5-IO heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is CH, R3 is CHR4R5, and one of R4 and R5 is C 1-6 alkyl and the other is C6-10 aryl, or C5_io heterocyclyl, said aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A sub-embodiment of this invention is realized when said aryl and heterocyclyl in R4, R5 RO5 and R? are selected from the group consisting of phenyl, napthyl, furanyl, piperonyl, oxazolyl, oxadiazolyl, quinolyl, isoquinolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and thiazolyl, preferably phenyl or pyridyl.
A further embodiment of the compound of formula II is realized when A is selected from the group consisti
Figure imgf000010_0002
Figure imgf000010_0001
wherein R6, and R7 are as previously described. A sub-embodiment of this invention is realized
when A is
Figure imgf000010_0003
' , preferably
Examples of compounds of this invention are found in Table 1 below: Table 1
Figure imgf000010_0004
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
tically acceptable salts and individual enantiomers and diastereomers thereof. Examples of these compouds are: N- [( 1 R)- 1 -(5 -fluoro- 1 -oxidopyridin-2-yl)ethyl] -3 -(5-methylpyridin-2-yl)-5- [(5 S)-5 -pyridin-2-yl-
4,5-dihydroisoxazol-3-yl]benzamide;
3-(5-methylpyridin-2-yl)-N-{(lR)-l-[l-oxido-6-(trifluoromethyl)pyridin-3-yl]ethyl}-5-[(5S)-5- pyridin-2-yl-4,5 -dihydroisoxazol-3 -yljbenzamide; 4'-methyl-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl)-N-[(lR)-l -(4H-1 ,2,4-triazol-3- yl)ethyl]biphenyl-3-carboxamide;
N-[(lR)-l-(3,5-difluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-(5-oxa-6-azaspiro[3.4]oct-
6-en-7-yl)benzamide;
2'-fluoro-4'-methyl-5-[(5S)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]-N-[(lR)-l-(4H-l,2,4- triazol-3-yl)ethyl]biphenyl-3-carboxamide;
N-[(3,5-difluoropyridin-2-yl)methyl]-3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5- dihydroisoxazol-3 -yl] benzamide ;
3-(5-chloropyridin-2-yl)-N-[(lR)-l-(5-fluoropyridin-2-yl)ethyl]-5-[(5S)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzamide; N-[(lR)-l-(5-fluoropyridin-2-yl)ethyl]-3-(5-hydroxy-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl)-5-
(5 -methylpyridin-2-yl)benzamide;
N-[(lR)-l-(5-fluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzamide;
3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]-N-{(lR)-l-[6- (trifluoromethyl)pyridin-3-yl]ethyl}benzamide;
N-[(lR)-l-(5-fluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-[(5R)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzamide;
3 -(5-methylpyridin-2-yl)-5- [(5R)-5-pyridin-2-yl-4,5 -dihydroisoxazol-3 -yl] -N- { ( 1 R)- 1 - [6-
(trifluoromethyl)pyridin-3-yl]ethyl}benzamide; 3-(5-methylpyridin-2-yl)-5-(l,3-oxazol-2-yl)-N-{(lR)-l-[l-oxido-6-(trifluoromethyl)pyridin-3- yl] ethyl } benzamide ;
N-[(lR)-l-(3-methyl-l,2,4-oxadiazol-5-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-(l,3-oxazol-2- yl)benzamide; or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof
When any variable (e.g. aryl, heterocycle, Rl, R^ etc.) occurs more than one time in any constituent, its definition on each occurrence is independent at every other occurrence. Also, combinations of substituents/or variables are permissible only if such combinations result in stable compounds. When Ra is -O- and attached to a carbon it is referred to as a carbonyl group and when it is attached to a nitrogen (e.g., nitrogen atom on a pyridyl group) or sulfur atom it is referred to a N-oxide and sulfoxide group, respectively. As used herein, "alkyl" encompasses groups having the prefix "alk" such as, for example, alkoxy, alkanoyl, alkenyl, and alkynyl and means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, and heptyl. "Alkenyl" refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. Preferably, alkenyl is C2-C6 alkenyl. Preferred alkynyl are C2-C6 alkynyl.
"Alkenyl," "alkynyl" and other like terms include carbon chains containing at least one unsaturated C-C bond. As used herin, "fluoroalkyl" refers to an alkyl substituent as described herin containing at least one flurine substituent.
The term "cycloalkyl" refers to a saturated hydrocarbon containing one ring having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term "C 1-6" includes alkyls containing 6, 5, 4, 3, 2, or 1 carbon atoms
The term "alkoxy" as used herein, alone or in combination, includes an alkyl group connected to the oxy connecting atom. The term "alkoxy" also includes alkyl ether groups, where the term 'alkyl' is defined above, and 'ether' means two alkyl groups with an oxygen atom between them. Examples of suitable alkoxy groups include methoxy, ethoxy, n- propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, methoxymethane (also referred to as 'dimethyl ether'), and methoxyethane (also referred to as 'ethyl methyl ether').
As used herein, "aryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, napthyl, tetrahydronapthyl, indanyl, or biphenyl. The term heterocycle, heterocyclyl, or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. The term heterocycle or heterocyclic includes heteroaryl moieties. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamoφholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl. An embodiment of the examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, 2- pyridinonyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamorpholinyl, thiamoφholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, thienyl and triazolyl.
In certain embodiments, the heterocyclic group is a heteroaryl group. As used herein, the term "heteroaryl" refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, between one and about three heteroatoms selected from the group consisting of N, 0, and S. heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazoiyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, and isoxazolyl. In certain other embodiments, the heterocyclic group is fused to an aryl or heteroaryl group. Examples of such fused heterocycles include, without limitation, tetrahydroquinolinyl and dihydrobenzofuranyl.
The term "heteroaryl", as used herein except where noted, represents a stable 5- to 7-membered monocyclic- or stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, such as piperidinyl, partially saturated, or unsaturated, such as pyridinyl, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heteroaryl groups include, but are not limited to, benzimidazole, benzisothiazole, benzisoxazole, benzofuran, benzothiazole, benzothiophene, benzotriazole, benzoxazole, carboline, cinnoline, furan, furazan, imidazole, indazole, indole, indolizine, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and N-oxides thereof.
Examples of heterocycloalkyls include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, imidazolinyl, pyrolidin-2-one, piperidin-2-one, and thiomorpholinyl. The term "heteroatom" means O, S or N, selected on an independent basis.
A moiety that is substituted is one in which one or more hydrogens have been independently replaced with another chemical substituent. As a non-limiting example, substituted phenyls include 2-flurophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2,4fluor-3- propylphenyl. As another non-limiting example, substituted n-octyls include 2, 4 dimethyl-5- ethyl-octyl and 3-cyclopentyloctyl. Included within this definition are methylenes (-CH2-) substituted with oxygen to form carbonyl (-CO-).
Unless otherwise stated, as employed herein, when a moiety (e.g., cycloalkyl, hydrocarbyl, aryl, alkyl, heteroaryl, heterocyclic, urea, etc.) is described as "optionally substituted" it is meant that the group optionally has from one to four, preferably from one to three, more preferably one or two, non-hydrogen substituents. Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-), nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, , alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups. Preferred substituents, which are themselves not further substituted (unless expressly stated otherwise) are:
(a) halo, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, and
(b) C1-C6 alkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, Ci-Cs alkyl, SO2CF3, CF3, Sθ2Me, Ci-Cs alkenyl, Ci-Cs alkoxy, Ci-Cs alkoxycarbonyl, aryloxycarbonyl, C2-C8 acyl, C2-C8 acylamino, Ci-Cs alkylthio, arylalkylthio, arylthio, Ci-Csalkylsulfinyl, arylalkylsulfnyl, arylsulfnyl, Ci-Cs alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C0-C6 N-alkylcarbamoyl, C2-C15 jV,iVdialkylcarbamoyl, C3-C7 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclyl, or aryl, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above.
"Halogen" refers to fluorine, chlorine, bromine and iodine. The term "mammal" "mammalian" or "mammals" includes humans, as well as animals, such as dogs, cats, horses, pigs and cattle.
All patents, patent applications and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety and are deemed representative of the prevailing state of the art.
As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, for example, reference to "a primer" includes two or more such primers, reference to "an amino acid" includes more than one such amino acid, and the like.
The phrases "effective amount" or "therapeutically effective amount" mean a concentration of P2X receptor complex modulator sufficient to inhibit or enhance the effect of the P2X receptor complex.
"Pain" means the more or less localized sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings. There are many types of pain, including, but not limited to, lightning pains, phantom pains, shooting pains, acute pain, inflammatory pain, neuropathic pain, complex regional pain, neuralgia, neuropathy, tissue injury pain, and the like (Dorland's Illustrated Medical Dictionary, 28th Edition, W. B. Saunders
Company, Philadelphia, Pa.). The goal of treatment of pain is to reduce the degree or severity of pain perceived by a treatment subject.
"Treating" or "treatment of a disease state includes: 1) preventing the disease state, i.e. causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state, but does not yet experience or display symptoms of the disease state; 2) inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms; 3) or relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
Compounds described herein may contain one or more double bonds and may thus give rise to cis/trans isomers as well as other conformational isomers. The present invention includes all such possible isomers as well as mixtures of such isomers unless specifically stated otherwise.
The compounds of the present invention may contain one or more asymmetric centers and may thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers.
It will be understood that, as used herein, references to the compounds of structural formula I are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or in other synthetic manipulations.
The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N, N -dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and tromethamine. When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
The pharmaceutical compositions of the present invention comprise compounds of the invention (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents or adjuvants. Such additional therapeutic agents can include, for example, i) opiate agonists or antagonists, ii) calcium channel antagonists, iii) 5HT receptor agonists or antagonists, iv) sodium channel antagonists, v) NMDA receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) NKl antagonists, viii) non-steroidal anti-inflammatory drugs ("NSAID"), ix) selective serotonin reuptake inhibitors ("SSRI") and/or selective serotonin and norepinephrine reuptake inhibitors ("SSNRI"), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xiii) valproate, xiv) neurontin (gabapentin), xv) pregabalin, and xvi) sodium channel blockers. The instant compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy. The present compounds and compositions are useful for the treatment of chronic, visceral, inflammatory and neuropathic pain syndromes. They are useful for the treatment of pain resulting from traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, small fiber neuropathy, and diabetic neuropathy. The present compounds and compositions are also useful for the treatment of chronic lower back pain, phantom limb pain, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain and related neuralgias, and pain associated with cancer, chemotherapy, HIV and HIV treatment-induced neuropathy. Compounds of this invention may also be utilized as local anesthetics. Compounds of this invention are useful for the treatment of irritable bowel syndrome and related disorders, as well as Crohn's disease. The instant compounds have clinical uses for the treatment of epilepsy and partial and generalized tonic seizures. They are also useful for neuroprotection under ischaemic conditions caused by stroke or neural trauma and for treating multiple sclerosis. The present compounds are useful for the treatment of tachy-arrhythmias. Additionally, the instant compounds are useful for the treatment of neuropsychiatric disorders, including mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety disorders. Thus, another aspect of this invention is the use of the compounds of formula I in the manufacture of a medicament to treat pain and other diseases associated with pain. In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats guinea pigs, or other bovine, ovine, equine, canine, feline, rodent such as mouse, species can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).
It will be appreciated that for the treatment of depression or anxiety, a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents, such as norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors
(SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRJs), α-adrenoreceptor antagonists, atypical anti-depressants, benzodiazepines, 5-HT1A agonists or antagonists, especially 5-HT]A partial agonists, neurokinin- 1 receptor antagonists, corticotropin releasing factor (CRF) antagonists, and pharmaceutically acceptable salts thereof.
Further, it is understood that compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited conditions and disorders, as well as to prevent other conditions and disorders associated with calcium channel activity. Creams, ointments, jellies, solutions, or suspensions containing the instant compounds can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention. Dosage levels from about 0.01 mg/kg to about 140 mg/kg of body weight per day are useful in the treatment of inflammatory and neuropathic pain, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammatory pain may be effectively treated by the administration of from about 0.0 lmg to about 75 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day. Neuropathic pain may be effectively treated by the administration of from about 0.01 mg to about 125 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 5.5 g per patient per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration to humans may conveniently contain from about 0.5 mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may ary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1 mg to about 1000 mg of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors. Such patient-related factors include the age, body weight, general health, sex, and diet of the patient. Other factors include the time and route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
In practice, the compounds of the invention, or pharmaceutically acceptable salts thereof, can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compounds of the invention, or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt. The compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more therapeutically active compounds. The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen. As described previously, in preparing the compositions for oral dosage form, any of the usual pharmaceutical media can be employed. For example, in the case of oral liquid preparations such as suspensions, elixirs and solutions, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used; or in the case of oral solid preparations such as powders, capsules and tablets, carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. In addition to the common dosage forms set out above, controlled release means and/or delivery devices may also be used in administering the instant compounds and compositions. In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used to form oral solid preparations such as powders, capsules and tablets.
Because of their ease of administration, tablets and capsules are advantageous oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques
A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet advantageously contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule advantageously containing from about 0.1 mg to about 500 mg of the active ingredient. Thus, a tablet, cachet, or capsule conveniently contains 0.1 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg of the active ingredient taken one or two tablets, cachets, or capsules, once, twice, or three times daily.
Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms. Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions, hi all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage, and thus should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, and dusting powder. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented of the invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid, such as, for example, where the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds. hi addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants). Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound of the invention, or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.
Further, as described above, the instant compounds can be utilized in combination with one or more therapeutically active compounds. In particular, the inventive compounds can be advantageously used in combination with i) opiate agonists or antagonists, ii) other calcium channel antagonists, iii) 5HT receptor agonists or antagonists, including 5-HT1A agonists or antagonists, and 5-HT1 A partial agonists, iv) sodium channel antagonists, v) N-methyl-D- aspartate (NMDA) receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) neurokinin receptor 1 (NKl) antagonists, viii) non-steroidal anti-inflammatory drugs (NSAID), ix) selective serotonin reuptake inhibitors (SSRI) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xiii) valproate, xiv) norepinephrine reuptake inhibitors, xv) monoamine oxidase inhibitors (MAOIs), xvi) reversible inhibitors of monoamine oxidase (RIMAs), xviijalpha- adrenoreceptor antagonists, xviii) atypical anti-depressants, xix) benzodiazepines, xx) corticotropin releasing factor (CRF) antagonists, xxi) neurontin (gabapentin) and xxii) pregabalin The abbreviations used herein have the following meanings (abbreviations not shown here have their meanings as commonly used unless specifically stated otherwise): Ac (acetyl), Bn (benzyl), Boc (tertiary-butoxy carbonyl), Bop reagent (benzotriazol-1- yloxy)tris(dimethylamino)phosonium hexafluorophosphate, CAMP (cyclic adenosine-3',5'- monophosphate), DAST ((diethylamino)sulfur trifluoride), DBU (l,8-diazabicyclo[5.4.0]undec- 7-ene), DIBAL (diisobutylaluminum hydride), DIEA (diisopropylethyl amine), DMAP (4- (dimethylamino)pyridine), DMF (N,N-dimethylformamide), DPPF (1,1 '-bisdiphenylphosphino ferrocene), EDC (l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), Et3N (triethylamine), GST (glutathione transferase), HOBt (1-hydroxybenzotriazole), LAH (lithium aluminum hydride), Ms (methanesulfonyl; mesyl; or SO2Me), MsO (methanesulfonate or mesylate), MCPBA (meto-chloro perbenzoic acid), NaHMDS (sodium hexamethyldisilazane), NBS (N-bromosuccinimide), NCS (N-chlorosuccinimide), NSAID (non-steroidal antiinflammatory drug), PDE (Phosphodiesterase), Ph (Phenyl), r.t. or RT (room temperature), Rac (Racemic), SAM (aminosulfonyl; sulfonamide or SO2NH2), SPA (scintillation proximity assay), Th (2- or 3-thienyl), TFA (trifluoroacetic acid), THF (Tetrahydrofuran), Thi (Thiophenediyl), TLC (thin layer chromatography), TMEDA (N5N5N', N'-tetramethylethylenediamine), TMSI (trimethylsilyl iodide), Tr or trityl (N-triphenylmethyl), C3H5 (AlIyI)5 Me (methyl), Et (ethyl), n- Pr (normal propyl), i-Pr (isopropyl), n-Bu (normal butyl), i-Butyl (isobutyl), s-Bu (secondary butyl), t-Bu (tertiary butyl), c-Pr (cyclopropyl), c-Bu (cyclobutyl), c-Pen (cyclopentyl), c-Hex (cyclohexyl).
The present compounds can be prepared according to the procedures provided in the Examples. The following Examples further describe, but do not limit, the scope of the invention.
Unless specifically stated otherwise, the experimental procedures were performed under the following conditions: All operations were carried out at room or ambient temperature; that is, at a temperature in the range of 18-25 °C. Inert gas protection was used when reagents or intermediates were air and moisture sensitive. Evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000pascals: 4.5-30 mm Hg) with a bath temperature of up to 60 °C. The course of reactions was followed by thin layer chromatography (TLC) or by high-pressure liquid chromatography-mass spectrometry (HPLC-MS), and reaction times are given for illustration only. The structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data. When given, yields are for illustration only. When given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz, 400 MHz or 500 MHz using the indicated solvent. Conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. Broad; etc. In addition, "Ar" signifies an aromatic signal. Chemical symbols have their usual meanings; the following abbreviations are used: v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).
The procedures described herein for synthesizing the compounds may include one or more steps of protecting group manipulations and of purification, such as, re-crystallization, distillation, column chromatography, flash chromatography, thin-layer chromatography (TLC), radial chromatography and high-pressure chromatography (HPLC). The products can be characterized using various techniques well known in the chemical arts, including proton and carbon- 13 nuclear magnetic resonance (1H and 13C NMR), infrared and ultraviolet spectroscopy (IR and UV), X-ray crystallography, elemental analysis and HPLC and mass spectrometry (HPLC-MS). Methods of protecting group manipulation, purification, structure identification and quantification are well known to one skilled in the art of chemical synthesis.
Appropriate solvents are those which will at least partially dissolve one or all of the reactants and will not adversely interact with either the reactants or the product. Suitable solvents are aromatic hydrocarbons (e.g, toluene, xylenes), halogenated solvents (e.g, methylene chloride, chloroform, carbontetrachloride, chlorobenzenes), ethers (e.g, diethyl ether, diisopropylether, tert-butyl methyl ether, diglyme, tetrahydrofuran, dioxane, anisole), nitriles (e.g, acetonitrile, propionitrile), ketones (e.g, 2-butanone, dithyl ketone, tert-butyl methyl ketone), alcohols (e.g, methanol, ethanol, n-propanol, iso-propanol, n-butanol, t-butanol), N,N-dimethyl formamide (DMF), dimethylsulfoxide (DMSO) and water. Mixtures of two or more solvents can also be used. Suitable bases are, generally, alkali metal hydroxides, alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, and calcium hydroxide; alkali metal hydrides and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride; alkali metal amides such as lithium amide, sodium amide and potassium amide; alkali metal carbonates and alkaline earth metal carbonates such as lithium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, and cesium hydrogen carbonate; alkali metal alkoxides and alkaline earth metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and magnesium ethoxide; alkali metal alkyls such as methyllithium, n-butyllithium, sec-butyllithium, t-bultyllithium, phenyllithium, alkyl magnaesium halides, organic bases such as trimethylamine, triethylamine, triisopropylamine, N,N-diisopropylethyl amine, piperidine, N-methyl piperidine, morpholine, N-methyl morpholine, pyridine, collidines, lutidines, and 4-dimethylaminopyridine; and bicyclic amines such as DBU and DABCO. It is understood that the functional groups present in compounds described in the examples below can be further manipulated, when appropriate, using the standard functional group transformation techniques available to those skilled in the art, to provide desired compounds described in this invention.
It is also understood that compounds of this invention contain one or more stereocenters that may be prepared as single enantiomers or diastereomers, or as mixtures containing two or more enantiomers or diastereomers in any proportion.
Other variations or modifications, which will be obvious to those skilled in the art, are within the scope and teachings of this invention. This invention is not to be limited except as set forth in the following claims. Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples. Starting materials are made according to procedures known in the art or as illustrated herein.
The compounds of the present invention can be prepared readily according to the following Schemes and specific examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art but are not mentioned in greater detail. The general procedures for making the compounds claimed in this invention can be readily understood and appreciated by one skilled in the art from viewing the following Schemes.
REACTION SCHEMES
The preparation of final compounds can proceed through general strategies depicted below. The following examples are typically exemplified by one strategy; however, other strategies could be employed by one skilled in the art.
Figure imgf000052_0001
metal catalyzed cross coupling
Figure imgf000052_0002
Isoxazoles can be prepared according to Scheme 1. Bromide 1 is oxidized to aldehyde 2_ which can be coupled with a range of aryl boronic acids under transition metal catalysis to give biaryl 3. Condensation with hydroxylamine gives oxime 4. Chlorination is followed by direct cyclization with a variety of alkynes to deliver isoxazole 5. Final deprotection and amide coupling under standard conditions gives the product 6.
SCHEME 1
Figure imgf000053_0001
Alternatively isoxazoles can be prepared as depicted in Scheme 2, in which the synthetic steps have been reordered to allow for the production of the isoxazoles as the ultimate step.
SCHEME 2
Figure imgf000053_0002
Isoxazolines can be prepared according to Scheme 3. Chlorination of oxime 4 is followed by direct cyclization with a variety of alkenes to deliver isoxazoline 8. Final deprotection and amide coupling under standard conditions gives the product 9.
SCHEME 3
Figure imgf000054_0001
Alternatively isoxazolines can be prepared as depicted in Scheme 4, in which the synthetic steps have been reordered to allow for the production of the isoxazoline as the ultimate step.
SCHEME 4
Figure imgf000054_0002
hi yet another modification the isoxazolines can be prepared as depicted in Scheme 5, in which the synthetic steps have been reordered to allow for the construction of the biaryl core as the ultimate step.
SCHEME 5
Figure imgf000055_0001
Pd-catalyst
Figure imgf000055_0002
Figure imgf000055_0003
Figure imgf000055_0004
SCHEME 6
Amine intermediates of type J_8 can be prepared from one of several intermediates as shown in Scheme 6. This method utilizes diastereoselective Ellman sulfinimine addition chemistry to generate a pair of diastereomeric sulf namides. The diastereomers are separated by silica chromatography prior to HCl deprotection to give 18. Depending on the substrate either the R OT S Ellman reagent is utilized to favor the desired alpha methyl amino compound with the preferred stereo configuration shown.
DIBAL, -78 °C ^ ^
Het or Ar. C° Pd<°> ' Et0H H* or Ar.
X OU2Lt CHO
13 14 15
Het or
Figure imgf000055_0005
16
H,N' ^f-Bu . B 1. RMgBr Het or AK , NH,
15 Het or Ar V^ N -C^
(R or S) 2. HCI
17 18 In some cases the final product may be further modified, for example, by manipulation of substituents. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art. Moreover, in some cases the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products.
INTERMEDIATES AND EXAMPLES
The following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.
INTERMEDIATE 1
Figure imgf000056_0001
(liO-l-(5-Fluoropyridin-2-yl)ethanamine Step A: Ethyl 5-fluoropyridine-2-carboxylate
To a degassed solution of ethyl alcohol (400 mL) in a Parr steel bomb was added sodium acetate (43.3 g, 528 mmol), 2-bromo-5-fiuoropyridine (20 g, 114 mmol), 1,1'- bis(diphenylphosphino)ferrocene (2.27 g, 4.09 mmol) and palladium acetate (204 mg, 0.91 mmol). The vessel was put under nitrogen and sealed with Parr top. The atmosphere was displaced with carbon monoxide gas and the pressure was adjusted to 300 psi. The mixture was heated to 90 0C. After 3 h, the pressure dropped to below 100 psi. The vessel was cooled to ambient temperature and the reaction was repressurized with carbon monoxide to 300 psi. The vessel was heated to 90 0C for an additional 4 h. The vessel was cooled to ambient temperature and the remaining carbon monoxide was vented. The mixture was concentrated to half of the volume. Ethyl acetate (500 mL) and water (300 mL) were added. The organic layer was isolated and the aqueous layer was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 70% hexanes/ ethyl acetate) gave the title compound (16 g). MS 170.0 (M+ 1).
Step B: 5-Fluoropyridine-2-carbaldehvde
To a solution of ethyl 5-fluoropyridine-2-carboxylate (25 g, 148 mmol) in tetrahydrofuran (250 mL) at -78 0C was added dropwise diisobutylaluminum hydride (1.0 M in hexanes; 296 mL, 296 mmol). After 1 h, the reaction was quenched with ethyl alcohol (10 mL). Saturated aqueous sodium potassium tartrate tetrahydrate (1.3 L) was added and the aqueous layer was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered. The solution mixture (1.4 L) was carried onto the next step without concentration. MS 125.9 (M+l).
Step C : JV- |Y 1 EH5-Fluoropyridin-2-yl)methylene] -2-methylpropane-2-sulfinamide
To a solution of 5-fluoropyridine-2-carbaldehyde (18.49 g, 148 mmol) in ethyl acetate (850 mL), THF (250 mL) and hexanes (300 mL) were added (i?)-(+)-2-methyl-2- propanesulfinamide (19.71 g, 163 mmol) and anhydrous copper(II) sulfate (59.0 g, 370 mmol). The mixture was stirred at ambient temperature. After 18 h, the mixture was filtered through Celite. The filtered cake was washed with ethyl acetate and the filtrate was concentrated. Purification by silica gel chromatography (100% dichloromethane —*■ 98% dichloromethane/ methanol) gave the title compound (33.7 g).
Step D: JV-[CIi?)-! -(5-Fluoropyridin-2-yl')ethyll-2-methylpropane-2-sulfinamide
To a solution of JV-[(lE)-(5-fluoropyridin-2-yl)methylene]-2- methylpropane-2-sulfinamide (52.12 g, 228 mmol) in dichloromethane (1000 mL) at -78 0C was added methylmagnesium bromide (3.0 M in THF; 198 mL, 594 mmol). The mixture was allowed to warm to ambient temperature. After 30 min, the mixture was cooled down to -78 0C and was quenched with saturated aqueous ammonium chloride (100 mL). The mixture was allowed to warm to ambient temperature. The organic layer was separated and the aqueous layer was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% ethyl acetate) gave the title compound (34.3 g). MS 245 (M+l).
Step Ε: (li?M-(5-Fluoropyridin-2-yDethanamine
To a solution of JV-[(l-/?)-l-(5-fluoropyridin-2-yl)ethyl]-2-methylpropane- 2-sulfinamide (34.3 g, 140 mmol) in methyl alcohol (700 mL) at 0 0C was added hydrogen chloride (4.0 M in dioxane; 105 mL, 421 mmol). After 30 min, the mixture was concentrated to dryness. The residue was recrytalized using ethyl alcohol (15 mL) and ether (40 mL). The white solid was filtered and dried under reduced pressure to give the hydrochloride salt of the title compound (25.6 g). MS 141.1 (M+l).
INTERMEDIATE 2
Figure imgf000058_0001
(li?)-l-[6-(Trifluoromethyl)pwidin-3-yl]etanamine
Step A: 2-methyl-iV- { ( 1 E)- [6-(trifluoromethyl )-3-pyridinyl]methylene ) -2-propanesulfinamide To a solution of 6-(trifluoromethyl)nicotinaldehyde (45.0 g, 257 mmol) in dichloroethane (640 mL) were added (S)-(-)-2-methyl-2-propanesulfinamide (34.3 g, 283 mmol) and anhydrous copper(II) sulfate (82 g, 514 mmol). The mixture was stirred at 50 0C. After 48 h, the mixture cooled to ambient temperature. The reaction mixture was filtered through Celite. The filtered cake was washed with dichloromethane and the filtrate was concentrated to give the title compound (76.8g). MS 223.1 (M-tert-butyl +1)
Step B : 2-methyl-N- {( IR)-I- [6-(trifluoromethyl)-3 -pyridinyl] ethyl } -2-propanesulfinamide
To a solution of 2-methyl-N-{(l£)-[6-(trifluorornethyl)-3- pyridinyl]methylene}-2-propanesulfinamide (76.8 g, 276 mmol) in dichloromethane (920 mL) at -45 0C was added methylmagnesium bromide (3.0 M in THF; 184 mL, 552 mmol). The mixture was stirred at -45 0C for 4 h. The reaction mixture was warmed to
-20 0C. Additional methylmagnesium bromide (3.0 M in THF; 276 mL, 828 mmol) was added at -20 0C. The reaction mixture was warmed to 0 0C and was quenched with saturated aqueous ammonium chloride (300 mL). The mixture was allowed to warm to ambient temperature. The organic layer was separated and the aqueous layer was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. The concentrate was recrystallized using ethyl alcohol (500 mL). Then white solid was filtered and dried under reduced pressure (41.6 g). MS 295.0 (M+l).
Step C: (Ii0-l-r6-(trifluoromethyiy3-pyridinyl]ethanamine
To a solution of 2-methyl-N-{(li?)-l-[6-(trifluoromethyl)-3- pyridinyl] ethyl} -2-propanesulfinamide (41.6 g, 141 mmol) in methyl alcohol (470 mL) at 0 0C was added hydrogen chloride (4.0 M in dioxane; 106 mL, 424 mmol). After 30 min, the mixture was concentrated to dryness. The residue was recrystallized using ethyl alcohol (15 mL) and ether (40 mL). The white solid was filtered and dried under reduced pressure to give the hydrochloride salt of the title compound (26.3 g). MS 191.2 (M+l). 1H NMR (500 MHz, CD3 OD): δ 8.83 (d, J = 2.2 Hz, 1 H); 8.17 (d, J = 8.2 Hz, 1 H); 7.93 (d, J = 8.2 Hz, 1 H); 4.69 (q, J = 6.9 Hz, 1 H); 1.70 (d, J = 6.9 Hz, 3 H). INTERMEDIATE 3
Figure imgf000059_0001
( 1 S)- 1 -(4H- 1.2.4-Triazol-3 -vDethanamine
Step A: Benzyl [(liS)-2-amino-l-methyl-2-thioxoethyl]carbamate
To a solution of [(15)-2-amino-l-methyl-2-oxoethyl]carbamate (15.0 g, 67.5 mmol) in dichloromethane (337 mL) was added 2,4-bis-(4-methoxyphenyl)-l,3-dithia-2,4- diphosphetane 2,4-disulfide (15.01 g, 37.1 mmol) and the mixture was heated to 55 0C. After 1.5 h, the reaction was allowed to cool to ambient temperature and concentrated. Recrystallization from dichloromethane gave the title compound (13.4 g). MS 239.1 (M+l).
Step B: Benzyl rπ5)-l-(4H-1.2.4-triazol-3-vnethyllcarbamate
To a solution of benzyl[(15)-2-amino-l-methyl-2-tWoxoethyl]carbamate (13.4 g, 56.2 mmol) in ethanol (1.125 L) was added formic acid hydrazide (20.26 g, 337 mmol) and mercury(II) chloride (19.85 g, 73.1 mmol). After 1 h the reaction was filtered and concentrated. Saturated aqueous sodium carbonate and ethyl acetate were added. The organic layer was isolated and the aqueous layer was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and concentrated. A solution of the resulting residue in ethanol (1.125 L) was heated to 80 0C. After 16 h, the reaction was concentrated. Purification by silica gel chromatography (100% dichloromethane — >• 90% dichloromethane / methanol with 1% ammonium hydroxide) gave the title compound (8.7 g). MS 247.1 (M+l).
Step C: (15)-l-(4H-l,2,4-Triazol-3-vnethanamine
To a solution of benzyl[(15)-l-(4H-l,2,4-triazol-3-yl)ethyl]carbamate (8.6 g, 34.9 mmol) in ethanol (140 mL) was added 4 M hydrochloric acid in 1,4-dioxane (43.7 mL, 175 mmol) and 10% palladium on carbon (1.858 g, 1.746 mmol) and the mixture was pressurized to 47 psi under hydrogen. After 4 h, the reaction was depressurized and filtered. Concentration gave the title compound as a hydrochloride salt (6.6 g). MS 113.0 (M+l). 1H NMR (500 MHz, CD3OD): δ 8.82 (s, 1 H); 4.67 (q, J= 6.9 Hz, 1 H); 1.70 (dd, J= 6.9, 1.0 Hz, 3 H).
INTERMEDIATE 4
Figure imgf000060_0001
( 1 R)- 1 -(5-Fluoro- 1 -oxidopyrindin-2-yl)ethanamine
Step A: tert-Butyl [(IR)-I -(5 -fluoropyridin-2-yOethyl] carbamate
To a solution of the toluene sulfonic acid salt of (li?)-l-(5-fluoropyridin-2- yl)ethanamine (7.5 g, 24.0 mmol) in dichloromethane (96 mL) at 0 0C was added triethylamine (7.03 mL, 50.0 mmol) and di-tert-butyl dicarbonate (6.13 mL, 26.4 mmol). The mixture was allowed to warm to ambient temperature. After 16 hours, saturated aqueous sodium bicarbonate was added. The organic layer was isolated and the aqueous layer was extracted with dichloromethane (2x). The combined organic extracts were washed with brine, dried over magnesium sulfate, and filtered. Concentration gave the title compound (7.72 g). MS 241.1 (M+l).
Step B: tert-Butyl [(l/?)-l-(5-fluoro-l-oxidopyridin-2-yl)ethyl]carbamate
To a solution of tert-bntyl [(li?)-l-(5-fluoropyridin-2-yl)ethyl]carbamate (5.77 g, 24.0 mmol) in dichloromethane (96 mL) was added 3-chloroperbenzoic acid (6.51 g, 26.4 mmol). After 4.5 h, excess 3-chloroperbenzoic acid (0.59 g, 2.6 mmol) was added. After 72 h, saturated aqueous sodium sulfite was added. After 1 h, saturated aqueous sodium bicarbonate was added. The organic layer was isolated and the aqueous layer was extracted with dichloromethane (2x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and concentrated. Purification by silica gel chromatography (100% dichloromethane → 90% dichloromethane / methanol with 1% ammonium hydroxide) gave the title compound (5.45 g). MS 257.1 (M+l).
Step C: (li?yi-(5-Fluoro-l-oxidopyrindin-2-vPethanamine To a solution of tert-butyl [(li?)-l-(5-fluoro-l-oxidopyridin-2-yl)ethyl]carbamate
(1.47 g, 5.74 mmol) in dichloromethane (28.7 mL) was added 4 M hydrochloric acid in 1,4- dioxane (43.0 mL, 172 mmol). After 2 h, concentration gave the title compound as a hydrochloride salt (1.396 g). MS 157.1 (M+l). 1H NMR (500 MHz5 CD3OD): δ 8.55 (dd, J= 4.3, 2.4 Hz, 1 H); 7.70 (dd, J= 9.0, 6.7 Hz, 1 H); 7.52 (ddd, J= 9.1, 7.1, 2.4 Hz, 1 H); 4.80 (q, J= 7.0 Hz, I H); 1.74 (d, J= 7.0 Hz, 3 H).
INTERMEDIATE 5
Figure imgf000061_0001
( 1 R)- 1 - [ 1 -oxido-6-(trifluoromethyl)-3 -pyridinyliethanamine
Step A: tert-butyl {(li?)-l-[6-(trifluoromethyl)-3-pyridinyl1ethvUcarbamate
To a solution of (li?)-l-[6-(TrifIuoromethyl)pyridin-3-yl]ethanamine hydrochloride salt (0.554 g, 0.21 mmol) in dichloromethane (7.0 mL) were added di-tert-butyl dicarbonate (0.506g, 2.32 mmol) and triethylamine (0.969 mL, 6.95 mmol). The reaction mixture was stirred at ambient temperature for 4 h. Saturated aqueous ammonium chloride was added. The mixture was extracted with dichloromethane (3x). The combined organics extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated to give the title compound which was used directly in Step B (0.626 g).
Step B: tert-butyl {(li?)-l-|"l-oxido-6-(trifluoromethvπ-3-pyridinyllethyl>carbamate
To a solution of tert-butyl {(li?)-l-[6-(trifIuoromethyl)-3- pyridinyl] ethyl} carbamate (0.626 g, 2.157 mmol) in chloroform (10.0 mL) were added 2,6-di- tert-butyl-4-methylphenol (24 mg, 0.108 mmol) and 3-chloroperbenzoic acid (0.665 g, 2.70 mmol). The reaction mixture was stirred at 50 °C for 48 h. The reaction mixture was cooled to ambient temperature. Saturated aqueous sodium thiosulfate and saturated aqueous sodium bicarbonate were added. The mixture was extracted with dichloromethane (3x). The combined organics extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (75% hexanes/ ethyl acetate → 100% ethyl acetate) gave the title compound (140 mg). MS 307.0 (M+l).
Step C: (li?)-l-ri-oxido-6-(trifluoromethyl)-3-pyridinyl]ethanamine hydrochloride
To a solution of tert-butyl {(li?)-l-[l-oxido-6-(trifluoromethyl)-3- pyridinyl]ethyl}carbamate (140mg, 0.457 mmol) in dioxane (2 mL) was added hydrogen chloride (4.0 M in dioxane; 0.343 mL, 1.371 mmol). The reaction mixture was stirred for 4 h. The reaction mixture was concentrated to dryness to give the hydrochloride salt of the title compound (118mg). MS 207.1 (M+l).
INTERMEDIATE 6
Figure imgf000062_0001
( 1 RV 1 -(3-methyl- 1 ,2,4-oxadiazol-5-yl)ethanamine
Step A: tert-butyl |"αR)-l-(3-methyl-L2.4-oxadiazol-5-vπethyl]carbaniate
To a solution of N-(tert-butoxycarbonyl)-D-alanine (20 g, 106 mmol), acetamide oxime (17.3 g, 234 mmol) in 120 mL of 1 ,4-dioxane and 30 mL of N, jV-dimethylformamide were added EDC (44.8 g, 234 mmol). The mixture was heated at 60 0C for 4 h and at 100 0C for 16 h. After cooling to ambient temperature, 300 mL of ethyl acetate was added into the reaction. The organic layer was washed by saturated sodium bicarbonate (2x). The organic were dried over magnesium sulfate, filtered and concentrated. The residue was purified by 0-10% methanol/dichloromethane gradient on silica column to give pure tert-butyl [( IR)-I -(3-methyl- l,2,4-oxadiazol-5-yl)ethyl]carbamate (6.0 g). MS 172.1 ((M-t-Butyl+H)+l).
Step B: (lRVl-C3-methyl-1.2,4-oxadiazol-5-yl)ethanamine
To a solution of tert-butyl [(lR)-l-(3-methyl-l,2,4-oxadiazol-5- yl)ethyl] carbamate (6.0 g, 26.4 mmol) in dioxane (40 mL) were added 4N hydrochloric acid in dioxane (30 mL). The reaction mixture was stirred at 20 0C for 16 h. The solution was concentrated and dried by vacuum to give hydrochloride salt of (IR)-I -(3 -methyl- 1,2,4- oxadiazol-5-yl)ethanamine (5.1 g). 1H NMR (500 MHz, CD3OD): δ 4.90-4.83 (m, 1 H); 2.41 (s, 3 H); 1.72 (d, J = 7.0 Hz, 3 H). MS 128.2 (M+l).
INTERMEDIATE 7 AND INTERMEDIATE 8
Figure imgf000062_0002
tert-Butyl 3-bromo-5-[(5i?V5-pyridin-2-yl-4,5-dihvdroisoxazol-3-yl"|benzoate and tert-butyl 3- bromo-5-[(55r)-5-pyridin-2-yl-4,5-dihvdroisoxazol-3-yl]benzoate
Step A: 3-bromo-5-(methoxycarbonvPbenzoic acid
To a solution of dimethyl 5-bromoisophthalate (6.2 g, 22.7 mmol) in methanol (10 mL) and tetrahydrofuran (10 mL) was added dropwise NaOH (1.0 M in water; 20.4 mL, 20.4 mmol). The reaction mixture was stirred at ambient temperature. After 18 h, the mixture was concentrated. Ethyl acetate was added and the mixture was extracted with water (2x). The combined aqueous layer was adjust to pH = 3 using HCl (6.0 M in water). This mixture was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated (4.9 g).
Step B: tert-butyl methyl 5-bromoisophthalate
To a solution of 3-bromo-5-(methoxycarbonyl)benzoic acid (4.9 g, 18.9 mmol) in tetrahydrofuran (100 mL) at 0 0C was added ΛyV-dimethylpyridin-4-amine (2.89 g, 23.6 mmol) followed by a solution of di-tert-butyl dicarbonate (6.23 g, 1.51 mmol) in tetrahydrofuran (20 mL). The mixture was allowed to warm to ambient temperature. After 72 h, the mixture was concentrated. Ethyl acetate was added and the mixture was washed with aqueous HCl (0.1 N), washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 80% hexanes /ethyl acetate) gave the title compound (3.63 g).
Step C: tert-butyl 3-bromo-5-fhydroxymethyl')benzoate
To a solution of tert-butyl methyl 5-bromoisophthalate (3.63 g, 11.5 mmol) in tetrahydrofuran (90 mL) at 0 °C was added portionwise sodium borohydride (1.53 g, 40.3 mmol). The mixture was stirred at 0 °C. After 30 min, methanol (4.2 mL, 92.0 mmol) was added and the mixture was heated to 40 °C. After 6 h, the mixture was cooled to ambient temperature and the mixture was quenched with methanol and concentrated. Ethyl acetate was added and the mixture was washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 50% hexanes /ethyl acetate) gave the title compound (2.7 g).
Step D: tert-butyl 3-bromo-5-formylbenzoate
To a suspension of potassium bromide (249.3 g, 2.095 mol), 2,2,6,6- tetramethylpiperidine 1-oxyl (3.27g, 20.93 mmol) in saturated aqueous sodium bicarbonate (960 mL) and water (240 mL) were added tert-butyl 3-bromo-5-(hydroxymethyl)benzoate (119.7 g, 417 mmol) and dichloromethane (1200 mL). The mixture was cooled to < 5 0C and sodium hypochlorite (850 mL, 12.53 mol) was added dropwise in 4 portions until the reaction completed. A solution of sodium thiosulfate pentahydrate (72 g) in water (250 mL) was added and the reaction mixture was warmed to ambient temperature. The organic layer was separated and the aqueous layer was extracted with dichloromethane (2x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated (119.0 g).
Step E: tβrt-Butyl 3-bromo-5-r(E)-(hvdroxyimino)methyllbenzoate To a solution of tert-butyl 3-bromo-5-formylbenzoate (119 g, 417 mmol) in dioxane (2.4 L) were added hydroxylamine hydrochloride (44.0 g, 633 mmol) and pyridine (103 mL, 1.27 mol). The reaction mixture was heated to 68 0C. After 16 h, the mixture was concentrated. Saturated aqueous amonium chloride was added the mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated (125.0 g). MS 243 (M - tert-butyl).
Step F: tert-Butyl 3-bromo-5-[(5i?)-5-pyridin-2-yl-4,5-dihvdroisoxazol-3-yl]benzoate and tert- buryl 3-bromo-5-[(5SV5-pwidin-2-yl-4,5-dihvdroisoxazol-3-yl'|benzoate To a solution of tert-butyl 3-bromo-5-[(E)-
(hydroxyimino)methyl]benzoate (125 g, 416 mmol) in iV,N-dimethylformamide (1680 mL) and dichloromethane (500 mL) was added JV-chlorosuccinimide (61.2 g, 458 mmol). The reaction mixture was heated to 50 0C. After 1 h, the reaction was cooled to ambient temperature and 2- vinylpyridine (90 mL, 833 mmol) was added. Triethylamine (350 mL, 2.51 mol) was added slowly over 30 min. The mixture was stirred at ambient temperature. After 30 min, water was added and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (2x), brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (90% heptane/ ethyl acetate → 70% heptane /ethyl acetate) gave 123.8 g of the mixture of two diastereomers. The two diastereomers were separated by supercritical fluid chromatography (ChiralPak AD, 2 cm x 25 cm, 80% carbon dioxide and 20% methanol, 70 mL/ min) gave tert-butyl 3-bromo-5-[(5i?)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzoate and tert-butyl 3-bromo-5-[(55)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzoate.
INTERMEDIATE 9
Figure imgf000064_0001
tert-Butyl 3-bromo-5-(5-oxa-6-azaspiro|'3.4'|oct-6-en-7-yl)benzoate Step A: tert-butyl 3-bromo-5-formylbenzoate
To a solution of tert-butyl 3-bromo-5-(hydroxymethyl)benzoate (0.8 g, 2.79 mmol) in dichloromethane (14 mL) at 0 0C was added Dess-Martin reagent (1.54 g, 3.62 mmol). The mixture was warmed to ambient temperature. After Ih, saturated NaHCO3 and saturated Na2SO3 were added the the mixture was extracted with dichloromethane (3x) The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 80% hexanes/ ethyl acetate) gave the title compound (440 mg).
Step B: tert-butyl 3-bromo-5-[(iTKhvdroxyirnino)methyl]benzoate
To a solution of tert-butyl 3-bromo-5-formylbenzoate (440 mg, 1.54 mmol) in dioxane (7 mL) were added hydroxylamine hydrochloride (107 mg, 1.54 mmol) and pyridine (0.13 mL, 1.54 mol). The reaction mixture was stirred at ambient temperature. After 72 h, additional hydroxylamine hydrochloride (29 mg, 0.29 mmol) and pyridine (25 μL, 0.31 mol) were added. The mixture was stirred at ambient temperature. Ater 3 h, the mixture was concentrated. Saturated aqueous NaHCO3 was added the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated (470 mg). MS 243 (M - tert-butyl).
Step C: tert-butyl 3-bromo-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl')ben2oate
To a solution of tert-butyl 3-bromo-5-[(E)-
(hydroxyimino)methyl]benzoate (5.26 g, 17.5 mmol) in jV,N-dimethylformamide (80 mL)) was added N-chlorosuccinimide (2.57 g, 19.3 mmol). The reaction mixture was heated to 50 0C. After 1 h, the reaction was cooled to ambient temperature and methylenecyclobutane (6.49 mL, 70.1 mmol) was added. Triethylamine (12.2 mL, 88.0 mol) was added. The mixture was stirred at ambient temperature. After 10 min, saturated aqueous NaHCO3 was added and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (2x), brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 90% hexanes /ethyl acetate) gave the title compound (2.86 g). MS 366 (M).
EXAMPLE 1
Figure imgf000065_0001
N-rdi?Vl-r5-Fluoropyridin-2-vnethvn-3-r5-methylpyridin-2-vn-5-r(55>)-5-pyridin-2-yl-4.5- dihvdroisoxazol-3-vHbenzamide Step 1 : tert-Butyl 3-(5-methylpyridin-2-vπ-5-r('55f)-5-pyridin-2-yl-4,5-dihvdroisoxazol-3- yllbenzoate
To a solution of tert-butyl 3-bromo-5-[(5iS)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzoate (19.95 g, 49.5 mmol) and bis(tri-tert-butylphosphine)palladium(0) (0.76 g, 1.48 mmol) in dioxane (247 mL) was added 5-methyl-2-pyridylzinc bromide (0.5 M in THF; 198 mL, 99 mmol). The reaction mixture was heated to 75 0C. After 1 h, the reaction was cooled to ambient temperature. Aqueous ethylenediaminetetraacetic acid tripotassium salt (0.4 M, 200 mL) and dichloromethane (200 mL) were added. The mixture was stirred for 15 min and the organic solvent was evaporated. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% ethyl acetate → 98% ethyl acetate/ methanol) gave the title compound (18.6 g). MS 416.1 (M+l).
Step B: 3-('5-Methylpyridin-2-yl)-5-|'('5^-5-pyridin-2-yl-4,5-dihvdroisoxazol-3-yl]benzoic acid To a solution of tert-butyl 3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-
4,5-dihydroisoxazol-3-yl]benzoate (18.6 g, 44.8 mmol) in dichloromethane (100 mL) was added hydrogen chloride (4.0 M in dioxane; 56.0 mL, 224 mmol). The reaction mixture was stirred at ambient temperature. After 18 h, the mixture was concentrated. Dichloromethane was added the suspension was filtered. The solid cake was washed with dihcloromethane and dried under reduced pressure gave the hydrochloride salt of the title compound (19.8 g). MS 359.8 (M+l).
Step C: N-rriieVl -(5-Fluoropyridin-2-vnethyl1-3-('5-methylpyridin-2-vn-5-r(5^)-5-pyridin-2-yl- 4,5-dihvdroisoxazol-3-yl]benzamide
To a solution of 3-(5-methylpyridin-2-yl)-5-[(5iS)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzoic acid (11.7 g, 27.1 mmol) in N,N-dimethylformamide (150 mL) were added (li?)-l-(5-fluoropyridin-2-yl)ethanamine hydrochloride salt (7.5 g, 35.2 mmol), EDC (7.78 g, 40.6 mmol), HOAT (1.84 g, 13.5 mmol) and triethylamine (26.4 mL, 189 mmol). The reaction mixture was heated to 50 0C. After 2 h, the mixture was cooled to ambient temperature and water was added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (3x), brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichloromethane → 40% dichloromethane/ acetone) gave the title compound (10.67 g). HRMS 482.1999 (M+l). 1H NMR (400 MHz, CDCh ): δ 8.57 (ddd, J= 4.8, 1.8, 1.0 Hz3 I H); 8.49 (d, J= 2.1 Hz, 1 H); 8.45-8.39 (m, 3 H); 8.16 (t, J= 1.6 Hz, 1 H); 7.71-7.66 (m, 2 H); 7.59-7.52 (m, 3 H); 7.37 (td, J= 8.3, 2.8 Hz, 1 H); 7.30 (dd, J= 8.6, 4.4 Hz, 1 H); 7.21 (ddd, J= 7.6, 4.9, 1.2 Hz, 1 H); 5.87 (dd, J= 10.7, 7.1 Hz, 1 H); 5.41-5.31 (m, 1 H); 3.92-3.78 (m, 2 H); 2.36 (s, 3 H); 1.55 (d, J= 6.8 Hz, 3 H). EXAMPLE IA
Figure imgf000067_0001
N-|riJ?Vl-r5-Fluoropyridin-2-vnethyll-3-(5-methylpyridin-2-vn-5-rr5igV5-pyridin-2-yl-4.5- dihydroisoxazol-3-yl~|benzamide
Step A: 3-(5-Methylpyridin-2-ylV5-f(5i?)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]benzoic acid
This compound was prepared using the same procedures that were used to prepare N-[(li?)-l-(5-fluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-[(55)-5-pyridin-2-yl- 4,5-dihydroisoxazol-3-yl]benzamide (step A and B, example 1). Step B: N-r(li?Vl-('5-Fluoropyridin-2-vnethyl1-3-('5-methylpyridin-2-ylV5-r('5igV5-pyridin-2-yl- 4.5-dihvdroisoxazol-3-yl]benzamide
To a solution of 3-(5-methylpyridin-2-yl)-5-[(5i?)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzoic acid trifluoracetate salt (1.14 g, 1.94 mmol) in NJ1J- dimethylformamide (10 mL) were added (li?)-l-(5-fluoropyridin-2-yl)ethanamine hydrochloride salt (0.62 g, 2.91 mmol), EDC (0.74 g, 3.88 mmol), HOAT (0.26 g, 1.94 mmol) and triethylamine (1.89 mL, 13.6 mmol). The reaction mixture was heated to 40 0C. After 1.5 h, additional (li?)-l-(5-fluoropyridin-2-yl)ethanamine hydrochloride salt (0.29 g, 1.36 mmol), EDC (0.37 g, 1.94 mmol), HOAT (0.13 g, 0.97 mmol) and triethylamine (0.54 mL, 3.88 mmol) were added. After 2 h, the mixture was cooled to ambient temperature and water was added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (3x), brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichloromethane → 95% dichloromethane/ methanol) gave the title compound (820 mg). The title compound was dissolved in dichloromethane and HCl (2.0 M in ether) was added. The mixture was concentrated gave the hydrochloride salt of the title compound. HRMS 482.2014 (M+ 1). 1H NMR (400 MHz, CD3OD): δ 8.82 (d, J= 5.8 Hz, 1 H); 8.75 (s, I H); 8.68-8.49 (m, 6 H); 8.42 (d, J= 8.4 Hz, 1 H); 8.19 (d, J= 8.1 Hz, 1 H); 8.07- 8.00 (m, 2 H); 7.92 (dd, J= 8.9, 4.6 Hz, 1 H); 6.28 (dd, J= 11.6, 6.8 Hz, 1 H); 5.36 (q, J= 7.1 Hz, I H); 4.30 (dd, J= 17.4, 11.7 Hz, I H); 3.98 (dd, J= 17.4, 6.8 Hz, 1 H); 2.61 (s, 3 H); 1.70 (d, J= 7.1 Hz, 3 H).
EXAMPLE 2
Figure imgf000068_0001
3-r5-Methylpyridin-2-ylV5-K5.S)-5-pyridin-2-yl-4.5-dihvdroisoxazol-3-yll-N-(ni?)-l-r6- (trifluoromethyl)pyridin-3 -yl] ethyl } benzamide To a solution of 3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzoic acid (2.9 g, 5.57 mmol) in ΛζTV-dimethylformamide (28 mL) were added (17?)-l-[6-(trifluoromethyl)pyridin-3-yl]etanamine hydrochloride salt (1.52 g, 6.69 mmol), EDC (1.60 g, 8.36 mmol), HOAT (190 mg, 1.39 mmol) and triethylamine (3.1 mL, 22.3 mmol). The reaction mixture was stirred at ambient temperature. After 2 h, the mixture was heated to 50 0C. After 1 h, the mixture was cooled to ambient temperature and saturated aqueous sodium bicarbonate was added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Ethyl acetate (200 mL) was added the mixture was heated to 70 0C. The solution was cooled and placed in the refrigerator for product to precipitate out. The precipiatated solid was filtered, washed with cold ethyl acetate and dried under reduced pressure gave the title compound (2.17 g). HRMS 532.1972 (M+ 1). 1U NMR (500, MHz, CDCl3) δ 8.80 (s, IH), 8.61- 8.60 (d, J= 4.9 Hz, IH), 8.51 (s, IH), 8.45-8.44 (m, 2H), 8.15 (t, J= 1.5 Hz, IH), 7.91-7.89 (m, IH), 7.74-7.71 (dd, J= 7.8, 6.1 Hz, 2H), 7.68-7.67 (d, J= 8.1 Hz, IH), 7.62-7.60 (m, IH), 7.57- 7.55 (d, J= 7.8 Hz, IH), 7.25-7.23 (m, IH), 6.69-6.67 (d, J= 6.8 Hz, IH), 5.93-5.89 (dd, J= 9.9, 7.9 Hz, IH), 5.44-5.38 (m, IH), 3.94-3.86 (m, 2H), 2.4 (s, 3H), 1.70-1.68 (d, J= 7.1 Hz, 3H).
EXAMPLE 2A
Figure imgf000068_0002
3-r5-Methylpyridin-2-vn-5-r(5i?V5-pyridin-2-yl-4,5-dihvdroisoxazol-3-yll-iV-{(li?Vl-r6- (trifluoromethyl)pyridin-3-yl]ethyUbenzamide
To a solution of 3-(5-memylpyridin-2-yl)-5-[(5i?)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzoic acid trifluoroacetate salt (1.14 g, 1.94 mmol) in N,N- dimethylformamide (10 mL) were added (li?)-l-[6-(trifluoromethyl)pyridin-3-yl]etanamine hydrochloride salt (0.77 g, 2.91 mmol), EDC (0.74 g, 3.88 mmol), HOAT (0.26 g, 1.94 mmol) and triethylamine (1.62 mL, 11.6 mmol). The reaction mixture was stirred at 40 0C. After 3.5 h, the mixture was cooled to ambient temperature and saturated aqueous sodium bicarbonate was added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Ethyl acetate (50 mL) was added the suspension was filtered. The solid was dried under reduced pressure gave 350 mg of the title compound. The filtrate was concentrated and purified by reverse phase HPLC (C-18, 95% water/ acetonitrile → 40% water/ acetonitrile with 0.1% trifluoroacetic acid) gave another 200 mg of the title compound (550 mg total). HRMS 532.1970 (M+ 1). 1H NMR (400 MHz, CDCh ): δ 8.76 (s, 1 H); 8.55 (d, J= 4.8 Hz, 1 H); 8.45 (s, 1 H); 8.38 (s, 2 H); 8.08 (s, 1 H); 7.86 (d, J= 8.2 Hz, 1 H); 7.73-7.59 (m, 3 H); 7.53 (dd, J= 18.7, 7.9 Hz, 2 H); 7.23-7.18 (m, 1 H); 6.85 (d, J= 7.0 Hz, 1 H); 5.86 (dd, J= 10.5, 7.3 Hz, 1 H); 5.42-5.32 (m, 1 H); 3.88-3.74 (m, 2 H); 2.35 (s, 3 H); 1.65 (d, J= 7.1 Hz, 3 H).
EXAMPLE 3
Figure imgf000069_0001
3-r5-methyl-2-pyridinyl)-N-{(li?)-l-ri-oxido-6-(trifluoromethyl)-3-pyridinyl1ethvn-5-rr55r)-5-r2- pyridinyl)-4,5-dihydro-3-isoxazolyl'|benzamide
Step A: 3 -(5 -methyl-2-ρyridinyl)-N- { ( 1 R)- 1 - \ 1 -oxido-6-(trifluoromethvn-3 -pyridinyliethyl 1-5- |'C55r)-5-(2-pyridinyl)-4.5-dihvdro-3-isoxazolyl1benzamide
To a solution of 3-(5-methylpyridin-2-yl)-5-[(5iS)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzoic acid (25 mg, 0.053 mmol) in N,N-dimethylformamide (0.5 mL) were added (li?)-l-[l-oxido-6-(trifluoromethyl)-3-pyridinyl]ethanamine hydrochloride salt (16 mg, 0.066 mmol), EDC (18 mg, 0.092 mmol), HOAT (2 mg, 0.016 mmol) and triethylamine (30 μL, 0.21 mmol). The reaction mixture was stirred at ambient temperature for 18 h. Saturated aqueous sodium bicarbonate was added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by reverse phase HPLC (C- 18, 95% water/ acetonitrile — »■ 5% water/ acetonitrile with 0.1% trifiuoroacetic acid) gave the trifluoroacetate salt of the title compound (26.4 mg). HRMS 548.1915 (M+ 1). 1H NMR (500 MHz, DMSO): δ 9.21 (d, J = 7.3 Hz, 1 H); 8.64-8.59 (m, 2 H); 8.58 (s, 1 H); 8.55 (s, 1 H); 8.53-8.50 (m, 1 H); 8.26 (s, 1 H); 8.07 (d, J = 8.1 Hz, 1 H); 7.94 (d, J = 8.4 Hz, 1 H); 7.89 (td, J = 7.7, 1.8 Hz, 1 H); 7.81 (dd, J = 8.1, 2.1 Hz, 1 H); 7.56 (t, J = 9.1 Hz, 2 H); 7.41 (ddd, J = 7.6, 4.8, 1.2 Hz, 1 H); 5.90 (dd, J = 11.1, 7.2 Hz3 I H); 5.22 (p, J = 7.1 Hz, 1 H); 4.01 (dd, J = 17.0, 11.1 Hz, 1 H); 3.89 (dd, J = 17.1, 7.2 Hz, 1 H); 2.38 (s, 3 H); 1.56 (d, J = 7.1 Hz, 3 H).
EXAMPLE 4
Figure imgf000070_0001
2'-fluoro-4'-methyl-5-rr5^)-5-(2-pyridinylV4.5-dihvdro-3-isoxazolyll-N-rd5f)-l-r4H-1.2.4- triazol-3 -vDethyl] -3 -biphenylcarboxamide To a solution of 2'-fluoro-4l-methyl-5-[(5S)-5-(2-pyridinyl)-4,5-dihydro-3- isoxazolyl]-3-biphenylcarboxylic acid (125 mg, 0.227 mmol) in NJV-dimethylformamide (1 mL) were added (15)-l-(4H-l,2,4-triazol-3-yl)ethanamine hydrochloride salt (52 mg, 0.283 mmol), EDC (65 mg, 0.340 mmol), ΗOAT (9 mg, 0.068 mmol) and triethylamine (95 μL, 0.680 mmol). The reaction mixture was stirred at ambient temperature for 18 h. Water was added. Purification by reverse phase ΗPLC (C-18, 95% water/ acetonitrile → 5% water/ acetonitrile with 0.05% ammonium hydroxide), and concentration gave the free base. Concentrate was taken up in dichloromethane into which hydrogen chloride gas was bubbled. Concentration gave the title compound as the hydrochloride salt (94.0 mg). ΗRMS 471.1977 (M+l). 1H NMR (500 MHz, CD3 OD): δ 8.94 (s, 1 H); 8.78 (d, J = 5.6 Hz, 1 H); 8.53 (t, J = 7.7 Hz, 1 H); 8.25 (t, J = 1.7 Hz, 1 H); 8.16 (t, J = 1.6 Hz, 1 H); 8.11-8.07 (m, 2 H); 7.94 (t, J = 6.6 Hz, 1 H); 7.46 (t, J = 7.9 Hz, 1 H); 7.15-7.07 (m, 2 H); 6.18 (dd, J = 11.4, 6.6 Hz, 1 H); 5.50-5.45 (m, 1 H); 4.21 (dd, J = 17.3, 11.5 Hz, I H); 3.86 (dd, J = 20.8, 7.9 Hz, 1 H); 2.41 (s, 3 H); 1.74 (d, J = 7.1 Hz, 3 H).
EXAMPLE 5
Figure imgf000071_0001
N-r(li?Vl-r3.5-difluoro-2-pyridinvnethvn-3-r5-methyl-2-pyridinvn-5-[(55)-5-r2-pyridinvn-4.5- dihydro-3 -isoxazolyll
To a solution of 3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl] benzoic acid (100 mg, 0.211 mmol) in Λζ,N-dimethylforrnamide (1 mL) were added (li?)-l-(3,5-difluoro-2-pyridinyl)ethanamine hydrochloride salt (51 mg, 0.264 mmol), EDC (71 mg, 0.370 mmol), HOAT (9 mg, 0.063 mmol) and triethylamine (147 μL, 1.06 mmol). The reaction mixture was stirred at ambient temperature for 18 h. Water was added. Purification by reverse phase HPLC (C-18, 95% water/ acetonitrile — ► 5% water/ acetonitrile with 0.1% trifluoroacetic acid) gave the trifluoroacetate salt. Saturated aqueous sodium bicarbonate was added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Concentrate was taken up in methanol into which hydrogen chloride gas was bubbled. Concentration gave the hydrochloride salt of the title compound (61.1 mg). HRMS 486.1728 (M+l). 1H NMR (500 MHz, CD3 OD): δ 8.85 (d, J = 5.9 Hz, 1 H); 8.78 (s, 1 H); 8.69-8.62 (m, 1 H); 8.58 (d, J = 8.4 Hz, 1 H); 8.54-8.50 (m, 3 H); 8.39 (d, J = 8.4 Hz, 1 H); 8.34 (d, J = 2.4 Hz, 1 H); 8.21 (d, J = 8.6 Hz, 1 H); 8.08-8.03 (m, 1 H); 7.63 (ddd, J = 9.8, 8.5, 2.4 Hz, 1 H); 6.34-6.28 (m, 1 H); 4.81 (s, 2 H); 4.31 (dd, J - 17.9, 11.8 Hz, 1 H); 4.00-3.93 (m, 1 H); 2.64 (s, 3 H).
Figure imgf000072_0001
3 -(5 -chloro-2-pyridinylViV- IY 1 R)- 1 -f 5-fluoro-2-pyridinvnethyll -5- |"C5Sr)-5-r2-pyridinvn-4.5 - dihydro-3 -isoxazolyl] benzamide Step A: 3-bromo-5-[(5SV5-(2-pyridinylV4.5-dihvdro-3-isoxazolyl]benzoic acid
To a solution of tert-butyl 3-bromo-5-[(5S)-5-(2-pyridinyi)-4,5-dihydro-3- isoxazolyljbenzoate (0.530 g, 1.31 mmol) in dioxane (6.5 mL) was added hydrogen chloride (4M in dioxane, 1.3 mL, 5.26 mmol). The reaction mixture was stirred at 50 °C for 2 h. Two drops of concentrated hydrogen chloride (12.1 N) were added. The reaction mixture was stirred at 50 °C for 2 d. The mixture was concentrated to dryness to give the hydrochloride salt of the title compound which was used directly in Step B (0.476 g). MS 346.9 (M+l).
Step B: 3-bromo-N-[πi?Vl-('5-fluoro-2-pyridmvnethvn-5-rr5^-5-('2-pyridinylV4.5-dihvdro-3- isoxazolyllbenzamide
To a solution of 3-bromo-5-[(5S)-5-(2-pyridinyl)-4,5-dihydro-3- isoxazolyl]benzoic acid hydrochloride(0.476 g, 1.24 mmol) in N^/V-dimethylformamide (6 mL) were added (li?)-l-(5-fluoropyridin-2-yl)ethanamine hydrochloride (0.330 g, 1.55 mmol), EDC (416 mg, 2.17 mmol), HOAT (0.051 g, 0.372 mmol) and triethylamine (0.865 mL, 6.20 mmol). The reaction mixture was stirred at ambient temperature for 18 h. Saturated aqueous sodium bicarbonate was added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (50% hexanes/ ethyl acetate — »• 0% hexanes/ ethyl acetate) gave the title compound (547 mg). MS 468.9 (M+l).
Step C: Λf-rriigVl-r5-fluoro-2-pyridinvnethyl1-3-r(55)-5-('2-pyridinylV4.5-dihvdro-3-isoxazolyl1- 5-C4.4.5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide
To a solution of 3-bromo-N-[(li?)-l-(5-fluoro-2-pyridinyl)ethyl]-5-[(55)-5-(2- pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide (0.547 g, 1.17 mmol) in dioxane (5.8mL) were added bis(pinacolato)diboron (0.444 g, 1.75 mmol), potassium acetate (0.229 g, 2.33 mmol), and dichloro[l,r-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.095 g, 0.117 mmol). The reaction mixture was stirred at 50 °C for 2 d. The reaction was cooled to ambient temperature and the mixture was filtered through Celite. The filtrate was concentrated. Saturated aqueous sodium bicarbonate was added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichloromethane — » 100% ethyl acetate) gave the title compound (0.547g). MS 517.1 (M+l).
Step D: 3-r5-chloro-2-pyridinvn-iV-f(li?Vl -(5-fluoro-2-pyridinvnethvn-5-r(5^-5-r2-pyridinvn- 4.5-dihydro-3-isoxazolyl]benzamide
To a solution of N-[(li?)-l-(5-fluoro-2-pyridinyl)ethyl]-3-[(55)-5-(2- pyridinyl)-4,5-dihydro-3-isoxazolyl]-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide - (0.150 g, 0.290 mmol) in N,N-dimethylformamide (2.2 mL) and water (0.73 mL) were added 2- bromo-5-chloropyridine (70 mg, 0.363 mmol), palladium acetate (3.3 mg, 0.015 mmol), 3,3',3"- phosphinidynetris(benzenesulfonic acid) trisodium salt (17 mg, 0.029 mmol) and diisopropylamine (104 μL, 0.73 mmol). The reaction mixture was heated to 80 °C. After 30 m, the mixture was cooled to ambient temperature and the solid was filtered off. Purification by reverse phase HPLC (C-18, 95% water/ acetonitrile → 5% water/ acetonitrile with 0.1% trifluoroacetic acid) gave the trifluoroacetate salt of the title compound. Saturated aqueous sodium bicarbonate was added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Concentrate was taken up in methanol into which hydrogen chloride gas was bubbled. Concentration gave the hydrochloride salt of the title compound (60.3 mg). HRMS 502.1434 (M+l). 1H NMR (500 MHz, CD3OD): δ 8.93 (t, J = 2.4 Hz, 1 H); 8.86 (d, J = 5.9 Hz, 1 H); 8.80 (d, J = 2.0 Hz, 1 H); 8.73-8.67 (m, 2 H); 8.60 (s, 1 H); 8.49-8.42 (m, 2 H); 8.26- 8.18 (m, 4 H); 8.09 (t, J = 6.8 Hz, 1 H); 6.31 (dd, J = 11.6, 6.5 Hz, 1 H); 5.44 (q, J = 7.1 Hz, 1 H); 4.32 (dd, J = 17.3, 11.6 Hz, 1 H); 4.00 (dd, J = 17.4, 6.7 Hz, 1 H); 1.80 (d, J = 7.2 Hz, 3 H).
EXAMPLE 7
Figure imgf000073_0001
N- IT 1 R)- 1 -f5-fluoro-2-pyridinvDethyll -3 - r5-hvdroxy-5-C2-pyridinyl )-4.5 -dihvdro-3 -isoxazolyll -5 -
(5 -methyl-2-pyridinyl)benzamide
Step A: methyl 3-(5-methyl-2-pyridinyl)-5-vinylbenzoate
To a solution of methyl 3-bromo-5-(5-methylpyridin-2-yl)benzoate (2.0 g, 6.53 mmol) in ethanol (13 mL) was added potassium vinyltrifluoroborate (1.31 g 9.80 mmol), triethylamine (1.37 mL, 9.80 mmol), and dichloro[l,l'- bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.267 g, 0.327 mmol). The reaction mixture was stirred and micro waved at 140 0C for 10 min. The reaction mixture was cooled to ambient temperature. Water was added, and ethanol was concentrated. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes — >■ 50% hexanes/ ethyl acetate) gave the title compound (1.51 g). MS 254.1 (M+l).
Step B: 3-(5-methyl-2-pyridinylV5-vinylbenzoic acid
To a solution of methyl 3-(5-methyl-2-pyridinyl)-5-vinylbenzoate (1.51 g, 5.97 mmol) in methanol (20 mL) was added sodium hydroxide (1 N, 17.9 mL, 17.9 mmol). The reaction mixture was stirred at 50 0C for 18 h. The mixture was cooled to ambient temperature, and hydrogen chloride (6N, 2.98 mL, 17.9, mmol) was added. The mixture was stirred for 30 min and was concentrated to dryness to give the tri-sodium chloride adduct of the title compound (2.5 g). MS 240.1 (M+l).
Step C: N-F(Ii?)-! -(5-fluoro-2-pyridinvπethyll-3-(5-methyl-2-pyridinyl')-5-vinylbenzamide To a solution of tri-sodium chloride adduct of 3-(5-methyl-2-pyridinyl)-5- vinylbenzoic acid (2.5 g, 6.0 mmol) in N,N-dimethylformamide (20 mL) were added (li?)-l-(5- Fluoropyridin-2-yl)ethanamine hydrochloride (1.60 g, 7.5 mmol), EDC (2.02 g, 10.5 mmol), HOAT (0.25 g, 1.8 mmol) and triethylamine (3.36 mL, 24 mmol). The reaction mixture was stirred at ambient temperature for 18 h. Saturated aqueous sodium bicarbonate was added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 100% ethyl acetate) gave the title compound (1.14 g). MS 362.1 (M+l).
Step D: N-Fd^)-I -('5-fluoro-2-pyridinyl')ethyl1-3-formyl-5-('5-methyl-2-pyridinyπbenzamide To a solution of N-[(li?)-l-(5-fluoro-2-pyridinyl)ethyl]-3-(5-methyl-2- pyridinyl)-5-vinylbenzamide (1.14 g, 3.15 mmol) in tetrahydrofuran (11 mL) and water (11 mL) were added sodium periodate (2.0 g, 9.45 mmol) and osmium tetroxide (2.5% in tert-butanol, 2.0 mL, 0.157 mmol). The reaction mixture was stirred at ambient temperature for 18 h. Saturated aqueous sodium sulfite and saturated aqueous sodium bicarbonate were added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated to give the title compound (1.1 g). MS 364.1 (M+l).
Step E: N-\(IRY\ -r5-fluoro-2-pyridinyl)ethyll-3-[('E)-rhvdroxyimino)methyl1-5-('5-methyl-2- pyridinvπbenzamide
To a solution of N-[(li?)-l-(5-fIuoro-2-pyridinyl)ethyl]-3-formyl-5-(5- methyl-2-pyridinyl)benzamide (1.10 g, 3.01 mmol) in dioxane (15 mL) hydroxylamine hydrochloride salt (0.314 g, 4.52 mmol) and pyridine (0.73 mL, 9.04 mmol). The reaction mixture was stirred at 70 °C for 18 h. The mixture was cooled to ambient temperature.
Saturated aqueous ammonium chloride and water were added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (95% dichloromethane/ methanol → 85% dichloromethane/ methanol) gave the title compound (0.91 g). MS 379.1 (M+l).
Step F: 3-({[(lJ?)-l-(5-fluoro-2-pyridinyl)ethyl1aminolcarbonyπ-N-hydroxy-5-(5-methyl-2- pyridinyPbenzenecarboximidoyl chloride
To a solution of N-[(17?)-l-(5-fluoro-2-pyridinyl)ethyl]-3-[(E)-
(hydroxyimino)methyl]-5-(5-methyl-2-pyridinyl)benzamide (0.703 g, 1.86 mmol)
Figure imgf000075_0001
dimethylformamide (1.9 mL) was added N-chlorosuccinimide (0.260 g, 1.95 mmol). The reaction mixture was stirred at 50 0C for 1 h. The temperature was raised to 70 °C for 1 h. The mixture was cooled to ambient temperature. Water was added. The mixture was extracted with diethyl ether (3x). The combined organic extracts were washed with water (3x), dried over magnesium sulfate, filtered and concentrated to give the title compound (0.795 g) MS 413.0 (M+l).
Step G: N-r(li?Vl-r5-fluoro-2-pyridinvnethyll-3-r5-hvdroxy-5-(2-pyridinylV4.5-dihvdro-3- isoxazolyll -5 -(5 -methyl -2 -pyridinvObenzamide
To a solution of 1 -(2-pyridinyl)ethanone (1.04 mL, 9.26 mmol) in tetrahydrofuran (15 mL) at -20 0C was added dropwise lithium bis(trimethylsilyl)amide (IM in hexanes, 9.26 mL, 9.26 mmol). The reaction mixture was stirred at -20 °C for 30 min. The reaction mixture was cooled to -78 °C. The reaction mixture was sequentially added (1 equivalent, ~5 mL, per portion) to a solution of 3-({[(li?)-l-(5-fluoro-2-pyridinyl)ethyl]amino}carbonyl)-N-hydroxy-5- (5-methyl-2-pyridinyl)benzenecarboximidoyl chloride (0.765 g, 1.85 mmol) in tetrahydrofuran (4 mL) at -78 °C. After addition of 5 equivalents (-25 mL), the reaction mixture was warmed to 0 °C. Saturated aqueous ammonium chloride was added. The mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Two purifications by silica gel chromatography (100% dichloromethane → 90% dichloromethane/ methanol, then 50% hexane/ ethyl acetate → 95% ethyl acetate/ methanol ) gave the title compound (0.221 g) HRMS 498.1956 (M+l). 1H NMR (500 MHz, CDCh ): δ 8.59 (d, J = 4.9 Hz, 1 H); 8.52 (s, 1 H); 8.49 (t, J = 1.6 Hz, 1 H); 8.46-8.42 (m, 2 H); 8.18 (s, 1 H); 7.83 (tdd, J = 7.7, 3.6, 1.6 Hz, 1 H); 7.73 (dd, J = 8.2, 2.3 Hz, 1 H); 7.71-7.67 (m, 1 H); 7.63 (dd, J = 7.9, 4.9 Hz, 1 H); 7.60 (d, J = 8.2 Hz, 1 H); 7.43-7.33 (m, 3 H); 5.44-5.36 (m, 1 H); 3.92 (dd, J = 17.7, 4.8 Hz, 1 H); 3.77 (dd, J = 17.7, 2.7 Hz, 1 H); 2.39 (s, 3 H); 1.72 (s, 1 H); 1.60 (d, J = 6.8 Hz, 3 H).
EXAMPLE 8
Figure imgf000076_0001
iV-r(li?Vl-('5-Fluoro-l-oxidopyridin-2-yl')ethyll-3-(5-methylpyridin-2-vn-5-[r5^-5-pyridin-2-yl- 4,5-dihvdroisoxazol-3-yl]benzamide
To a solution of 3-(5-methylpyridin-2-yl)-5-[(55)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl] benzoic acid (50.0 mg, 0.12 mmol) in iV^/V-dimethylformamide (1 mL) were added (li?)-l-(5-fiuoro-l-oxidopyridin-2-yl)ethanamine hydrochloride salt (33.4 mg, 0.17 mmol), EDC (33.3 mg, 0.17 mmol), HOAT (7.9 mg, 0.06 mmol) and triethylamine (0.11 mL, 0.81 mmol). The reaction mixture was stirred at ambient temperature for 1.5 h. The reaction mixture was heated to 50 0C. After 20 min, the mixture was cooled to ambient temperature and the solid in the reaction was filtered off. Purification by reverse phase chromatography (C-18, 95% water/ acetonitrile → 65% water/ acetonitrile with 0.1% trifluoroacetic acid) gave gave the title compound (46 mg). HRMS 498.1954 (M+l). 1H NMR (400 MHz, CDCl3): δ 8.56 (d, J= 4.8 Hz, 1 H); 8.48 (s, 1 H); 8.46-8.35 (m, 3 H); 8.15-8.08 (m, 2 H); 7.73-7.65 (m, 2 H); 7.54 (t, J= 8.9 Hz, 2 H); 7.34 (t, J= 7.8 Hz, 1 H); 7.20 (dd, J= 7.7, 4.8 Hz, 1 H); 7.06 (ddd, J= 8.8, 6.6, 2.4 Hz, 1 H); 5.86 (dd, J= 10.9, 6.9 Hz, 1 H); 5.58-5.48 (m, 1 H); 3.92-3.74 (m, 2 H); 2.35 (s, 3 H); 1.70 (d, J= 7.0 Hz, 3 H). EXAMPLE 9
Figure imgf000077_0001
S-rS-Methylpyridin^-vn-S-dJ-oxazol-l-vn-iV-iπRVl-ri-oxido-ό-rtrifluoroinethvnpyridin-S- yl] ethyl } benzamide
Step A: Methyl 3-f5-methylpyridin-2-yl)-5-π,3-oxazol-2-yl)benzoate
To a degassed solution of methyl 3-bromo-5-(5-methylpyridin-2-yl)benzoate (1.0 g, 3.27 mmol) in 1,4-dioxane (20 mL) was added cesium fluoride (1.49 g, 9.80 mmol), 2- (tributylstannyl)-l,3-oxazole (2.34 g, 6.53 mmol) and Bis(tri-t-butylphosphine) palladium (83 mg, 0.163 mmol). The mixture was heated to 90 0C under nitrogen for 16 h, after which the reaction was cooled to 20 0C. Ethyl acetate (200 mL) and saturated sodium bicarbonate solution (200 mL) were added. The organic layer was isolated and the aqueous layer was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was run through silica gel chromatography (100% dichloromethane → 95% dichloromethane/ methanol) to give the title compound (1 g). MS 295.1 (M+l).
Step B: 3-(5-methylpyridin-2-ylV5-π,3-oxazol-2-y0benzoic acid
To a solution of methyl 3-(5-methylpyridin-2-yl)-5-(l,3-oxazol-2-yl)benzoate (0.96 g, 3.26 mmol) in tetrahydrofuran (20 mL) at 20 0C was added 20 mL of 0.5 N sodium hydroxide solution. After 16 h at 20 0C, the reaction was quenched with 4N HCl in dioxane (5 mL). The titled compound was precipitated out as hydrochloride salt. After filtration, washed by
100 mL of ethyl ether twice and died under vacuum, the titled compound was obtained as pure hydrochloride salt (1.2 g). MS 281.0 (M+l).
Step C: 3-f5-rnethylpyridin-2-vn-5-fl.3-oxazol-2-vn-.V-(nRVl-ri-oxido-6- ftrifluoromethyl)pyridin-3-yl1ethyl}benzamide
To a solution of hydrochloride salt of 3-(5-methylpyridin-2-yl)-5-(l,3-oxazol-2- yl)benzoic acid (30 mg, 0.0850 mmol) in N, N-dimethylformamide (2 mL) were added (IR)-I-[I- oxido-6-(trifluoromethyl)pyridin-3-yl]ethanamine hydrochloride salt (31 mg, 0.128 mmol), EDC
(33 mg, 0.170 mmol), HOBT (26 mg, 0.170 mmol) and N, N-diisopropylethylamine (40 μL, 0.227 mmol). The reaction mixture was stirred at 20 0C for 16 h. The mixture was purified by reverse-phase HPLC gave the TFA salt of the title compound (40 mg). HRMS 469.1482 (M+ 1). 1H NMR (499 MHz, DMSO): δ 9.28 (d, J= 7.3 Hz, 1 H); 8.84 (t, J= 1.6 Hz, 1 H); 8.66 (t, J= 1.7 Hz5 I H); 8.59 (d, J= 9.1 Hz, 2 H); 8.52 (t, J= 1.6 Hz, 1 H); 8.33 (s, 1 H); 8.06 (d, J= 8.1 Hz, 1 H); 7.95 (d, J= 8.4 Hz, 1 H); 7.80 (dd, J= 8.1, 2.2 Hz, 1 H); 7.57 (d, J= 8.4 Hz, 1 H); 7.48 (s, 1 H); 5.27-5.20 (m, 1 H); 2.38 (s, 3 H); 1.57 (d, J = 7.1 Hz, 3 H).
EXAMPLE 10
Figure imgf000078_0001
■V-rflRVl-(3-metfayl-1.2.4-oxadϊazol-5-vnethyll-3-(5-methylpyridin-2-vn-5-fl.3-oxazol-2- vPbenzamide
To a solution of hydrochloride salt of 3-(5-methylpyridin-2-yl)-5-(l,3-oxazol-2- yl)benzoic acid (103 mg, 0.292 mmol) in N, N-dimethylformamide (4 mL) were added (lR)-l-(3- methyl-l,2,4-oxadiazol-5-yl)ethanamine hydrochloride salt (72 mg, 0.437 mmol), EDC (168 mg, 0.875 mmol), HOBT (134 mg, 0.875 mmol) and N, N-diisopropylethylamine (204 μL, 1.17 mmol). The reaction mixture was stirred at 20 0C for 16 h. The mixture was purified by reverse- phase HPLC gave the hydrochloride salt of the title compound (125 mg). HRMS 390.1560 (M+l). 1H NMR (500 MHz, CD3OD): δ 8.82-8.78 (m, 2 H); 8.74 (t, J= 1.7 Hz, 1 H); 8.61 (d, J= 8.2 Hz, 1 H); 8.52 (s, 1 H); 8.42 (d, J= 8.3 Hz, 1 H); 8.13 (d, J= 0.9 Hz, 1 H); 7.43 (d, J = 0.8 Hz, 1 H); 5.50 (q, J= 7.2 Hz, 1 H); 2.65 (s, 3 H); 2.39-2.35 (m, 3 H); 1.75 (d, J= 7.2 Hz, 3 H).
EXAMPLE 11
Figure imgf000079_0001
4'-Methyl-5-r5-oxa-6-azaspiror3.41oct-6-en-7-ylV7V-rα5f)-l-r4H-1.2.4-triazol-3- vπethyl]biphenyl-3-carboxaniide
Step A: tert-butyl 4'-methyl-5-(5-oxa-6-azaspiro['3.4'|oct-6-en-7-yDbiphenyl-3-carboxylate To a solution of tert-butyl 3-bromo-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7- yl)benzoate (1.36 g, 3.71 mmol) in THF (8 mL) and water (8 mL) were added (4- methylphenyl)boronic acid (1.01 g, 7.43 mmol), dichloro[l,l'- bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (82 mg, 0.11 mmol) and cesium carbonate (3.63 g, 11.1 mmol). The mixture was heated to 120 0C in a microwave reactor for 10 min. The mixture was cooled to ambient temperature and saturated aqueous NaHCO3 was added and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (2x), brine, dried over sodium sulfate, filtered and concentrated.
Purification by silica gel chromatography (100% hexanes → 85% hexanes /ethyl acetate) gave the title compound (1.26 g). MS 378.3 (M+ 1).
Step B: 4'-methyl-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl)biphenyl-3-carboxylic acid
To a solution of tert-butyl 4'-methyl-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7- yl)biphenyl-3-carboxylate (1.26 g, 3.34 mmol) in dichloromethane (12 mL) was added hydrogen chloride (4.0 M in dioxane; 4.17 mL, 16.7 mmol). The reaction mixture was stirred at ambient temperature. After 18 h, the mixture was concentrated. Dichloromethane was added and the suspension was filtered. The solid cake was washed with dihcloromethane and dried under reduced pressure gave the title compound (1.0 g). MS 322.2 (M+l).
Step C: 4'-Methyl-5-r5-oxa-6-azaspiror3.41oct-6-en-7-vn-iV-rri^-l-(4H-1.2.4-triazol-3- yllethyllbiphenyl-3-carboxamide
To a solution of 4'-methyl-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl)biphenyl- 3-carboxylic acid (0.15 g, 0.47 mmol) in 7V,N-dimethylformamide (3 mL) were added (IS)-I- (4H-l,2,4-triazol-3-yl)ethanamine hydrochloride salt (0.12 g, 0.65 mmol), EDC (0.13 g, 0.70 mmol), HO AT (0.06 g, 0.47 mmol) and triethylamine (0.39 mL, 2.80 mmol). The reaction mixture was heated to 50 0C. After 1 h, the mixture was cooled to ambient temperature.
Saturated aqueous NaHCO3 was added and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (3x), brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichloromethane → 90% dichloromethane/ methanol) gave the title compound (188 mg). The title compound was dissolved in dichloromethane and HCl (2.0 M in ether) was added. The mixture was concentrated gave the hydrochloride salt of the title compound. HRMS 416.2083 (M+l). 1H NMR (400 MHz, CD3OD): δ 9.35 (s, 1 H); 8.16 (t, J= 1.7 Hz, 1 H); 8.11 (t, J= 1.6 Hz, 1 H); 8.03 (t, J= 1.7 Hz, 1 H); 7.56 (d, J= 7.9 Hz, 2 H); 7.26 (d, J= 7.8 Hz, 2 H); 5.54-5.44 (m, 1 H); 3.69-3.45 (m, 2 H); 2.52-2.42 (m, 2 H); 2.35 (s, 3 H); 2.30-2.22 (m, 2 H); 1.77 (d, J= 7.1 Hz, 2 H).
EXAMPLE 12
Figure imgf000080_0001
N-U 1 R)- 1 -(3.5 -Difluoropyridin-2-vDethvH -3 -C5 -methylpyridin-2-ylV5 -f 5-oxa-6-azaspiro \3.41oct-
6-en-7-yl)benzamide
Step A: tert-buty\ 3-(5-methylpyridin-2-yl)-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl')berizoate To a solution of tert-butyl 3-bromo-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7- yl)benzoate (1.42 g, 3.88 mmol) and bis(tri-tert-butylphosphine)palladium(0) (59.0 mg, 0.12 mmol) in dioxane (20 mL) was added 5-methyl-2-pyridylzinc bromide (0.5 M in THF; 15.5 niL,
7.75 mmol). The reaction mixture was heated to 70 0C. After 1 h, the reaction was cooled to ambient temperature and the solvent was evaporated. Saturated aqueous sodium potassium tartrate was adde and the mixture was extracted with ethyl acetae (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated.
Purification by silica gel chromatography (100% hexanes → 75% hexanes/ ethyl acetate) gave the title compound (1.42 g). MS 379.2 (M+l).
Step B: 3-(5-methylpyridin-2-yl)-5-('5-oxa-6-azaspiro[3.4]oct-6-en-7-vπbenzoic acid
To a solution of tert-butyl 3-(5-methylpyridin-2-yl)-5-(5-oxa-6- azaspiro[3.4]oct-6-en-7-yl)benzoate (1.27 g, 3.36 mmol) in dichloromethane (8 mL) was added hydrogen chloride (4.0 M in dioxane; 5.05 mL, 20.1 mmol). The reaction mixture was stirred at ambient temperature. After 18 h, the mixture was concentrated. Dichloromethane was added and the suspension was filtered. The solid cake was washed with dihcloromethane and dried under reduced pressure gave the title compound (1.09 g). MS 323.2 (M+l). Step C: .V-rO-gy 1 -f3.5-difluoropyridϊn-2-vnethvn-3-f 5-methylpyridϊn-2-ylV5-(5-oxa-6- azaspuO[3.4]oct-6-en-7-yl*)benzamide
To a solution of 3-(5-methylpyridin-2-yl)-5-(5-oxa-6-azaspiro[3.4]oct-6- en-7-yl)benzoic acid (0.20 g, 0.56 mmol) in iV,N-dimethylformamide (2.5 mL) were added (Ii?)- l-(3,5-difluoropyridin-2-yl)ethanamine hydrochloride salt (0.13 g, 0.67 mmol), EDC (0.16 g, 0.70 mmol), HOAT (0.5 M in DMF; 0.56 mL, 0.28 mmol) and diisopropylethylamine (0.09 mL, 0.56 mmol). The reaction mixture was at ambient temperature and solid was filtered off. Purification by reverse phase HPLC (C-18, 95% water/ acetonitrile → 5% water/ acetonitrile with 0.1% trifluoroacetic acid). Clean fractions were combined and saturated aqueous NaHCO3 was added and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (3x), brine, dried over sodium sulfate, filtered and concentrated gave the title compound (150 mg). HRMS 463.1948 (M+ 1). 1H NMR (400 MHz, CDCl3): δ 8.51 (s, 1 H); 8.44 (t, J= 1.7 Hz, I H); 8.38 (t, J= 1.6 Hz, 1 H); 8.29 (d, J= 2.4 Hz, 1 H); 8.14 (t, J= 1.6 Hz, 1 H); 7.71 (d, J= 8.1 Hz, 1 H); 7.63 (d, J= 7.6 Hz, 1 H); 7.58 (dd, J= 8.1, 2.2 Hz, 1 H); 7.24-7.16 (m, 1 H); 5.71-5.61 (m, 1 H); 3.51 (s, 2 H); 2.62-2.50 (m, 2 H); 2.37 (s, 3 H); 2.26- 2.18 (m, 2 H); 1.90-1.79 (m, 1 H); 1.68-161 (m, 1 H); 1.54 (d, J= 6.7 Hz, 3 H).
Assay In vivo rat visceral pain model
Male Sprague-Dawley rats, weighing 150 - 180 g (max. range per experiment = 40 g) at the beginning of the experiments. Animals will be delivered to the laboratory at least 5 days before the experiments during which time they are acclimatized to laboratory conditions. Rats will be housed in groups of 4, 5 or 6 in macrolon cages (41 x 25 x 14 cm or 44 x 28 x 19 cm) on wood with free access to food and water until tested (or as indicated otherwise). The animal house will be maintained under artificial lighting (12 hours) between 7.00 and 19.00 in a controlled ambient temperature of 21 ± 3°C, and relative humidity maintained at 40-70%. Information related to any clinical signs and mortality will be archived with the study materials.
After overnight food-deprivation, male Sprague-Dawley rats are slightly anesthetized (isoflurane) and injected with 1% acetic acid into the colon (1.5 ml) using a cannula of 5 cm in length. After a recovery period of 75 minutes, rats are again slightly anesthetized (isoflurane) and a latex balloon of 1.5 cm in length tightly attached to a catheter is inserted via the anus into the descending colon and rectum. Anesthesia is then immediately discontinued. 15 minutes later, the test substance is administered p.o. 60 minutes after administration, the balloon is filled with 1.2 ml of water and the number of abdominal contractions is counted for 10 minutes. 10 rats are studied per group. The test is performed blind. The test substance will be evaluated at 3 doses, and compared with the vehicle group. Rats will be euthanized at the end of the experiments by exposure to a mixture of O2/CO2 (20%/80%) followed by CO2. Data will be analyzed by comparing treated groups with vehicle control using Mann Whitney U tests.
In vivo L5 spinal nerve ligation model a. Surgery and post-operative care
For the spinal nerve ligation (SNL) procedure, male Sprague Dawley rats (100-200 g; Harlan) are anesthetized using isoflurane (1-5%; inhalation). Using aseptic technique, a dorsal midline incision is made from approximately spinal nerve L3 to S2. A combination of sharp and blunt dissection is used to expose the L6/S1 posterior interarticular process. The L6 transverse process is visualized and removed, and the L4 and L5 spinal nerves are exposed distal to their emergence from the intervertebral foramina. The L5 nerve is then tightly ligated with 6-0 silk suture. The muscle is closed with 4-0 absorbable suture and the skin is closed with wound clips. Postoperative monitoring is carried out to assure that animals are exposed to the least amount of pain as possible. Animals are housed in pairs on bedding and are monitored (2x) daily for three days post-operatively by Laboratory Animal Resource staff and then daily by investigator for any signs of possible distress. b. Behavioral testing Prior to surgery, rats are tested for pre-surgery mechanical hind paw withdrawal thresholds by applying a series of calibrated von Frey filaments (0.25 - 15 g) to the left hind paw and determining the median withdrawal threshold using the Dixon "up-down" method (Chaplan et al., J Neurosci Meth 53:55, 1994). Rats are placed in individual plastic chambers on an elevated mesh galvanized steel platform and allowed to acclimate for 60 min. Pre-surgery mechanical hind paw withdrawal thresholds are determined, and rats having a threshold <15 g are excluded from the study. Following determination of pre-surgery withdrawal thresholds, rats undergo the SNL procedure described above. Between 28-35 days following the surgical procedure, rats are tested for post-surgery thresholds using the procedure described above, and animals displaying a hind paw withdrawal threshold <4.0 g are considered allodynic (i.e. mechanical hypersensitivity). Effects of test compounds on SNL-induced mechanical hypersensitivity are determined by dosing the compound along with a vehicle control group and a group receiving the positive comparator pregabalin (20 mg/kg, p.o.). Efficacy in the SNL model is evaluated by determining the % reversal of mechanical hypersensitivity using the formula: (post-drug threshold — post-surgery threshold) % reversal = X 100
(pre-surgery threshold - post-surgery threshold)
At the conclusion of the study, all rats are euthanized using CO2 and plasma and brain tissue are collected for bioanalytical analysis of drug exposures.
In vivo Complete Freunds adjuvant (CFA) model
Male Sprague Dawley rats (300-400 g; Charles River) receive an intradermal injection of CFA (200 ul, 0.5 mg/ml) into the plantar aspect of the left hind paw and are subsequently returned to their cages where they are maintained on soft bedding. 72 hrs following CFA injection rats are tested for post-CFA mechanical hind paw withdrawal thresholds by wrapping the rat in a towel and placing the hind paw (either left or right) in a modified Randall-Sellito paw pinch apparatus (Stoelting, Wood Dale, IL). A plastic bar attached to a lever is placed on the dorsum of the hind paw, and an increasing force is applied to the hind paw until the rat vocalizes or pulls its hind paw away from the bar. The rat's hind paw withdrawal threshold is recorded at that point. The mechanical stimulus is applied to each hind paw 2 times, and the average post- CFA mechanical hind paw withdrawal thresholds are determined for both the left and right hind paw. Following determination of post-CFA withdrawal thresholds, rats receive test compound, vehicle, or the positive comparator naproxen (30 mg/kg, p.o.), and effects of compounds on withdrawal thresholds for the inflamed (CFA) hind paw are determined. Efficacy in the CFA model is evaluated by determining the % reversal of mechanical hypersensitivity using the formula:
(post-drug threshold )eft hind paw - post-CFA threshold iea hind paw) % reversal = X 100
(post-CFA threshold right hind paw - post-CFA threshold ieft hind paw)
At the conclusion of the study, all rats are euthanized using CO2 and plasma and brain tissue are collected for bioanalytical analysis of drug exposures.
Cystometry in normal healthy rats Female Sprague-Dawley rats weighed 250-350 g were housed in a temperature- and light (12-h light/dark cycle)-controlled room, and were allowed access to food and water ad libitum. The animals were anesthetized with urethane (1.0 g/kg, i.p.). Supplemental urethane was given if necessarily. A lower abdominal midline incision was made to expose the bladder, and a polyethylene catheter (PE-50) was inserted into the bladder dome for recording the intravesical pressure and intravesical infusion of physiological saline at the rate of 0.05 ml/min. The intravesical pressure was measured using a pressure transducer, and signal was recorded using a multiple channel data acquisition system (Power lab, AD Instruments, Biopac systems, Colorado Springs, CO) at a sampling rate of 10 Hz. After confirming stable inter-micturtion interval and micturition pressure by intravesical infusion of saline, the drugs were administered intravenously (0.25 ml/kg). Intermicturition interval (functional bladder capacity) and micturition pressure (maximum intravesical pressure) were obtained from micturitions prior to dosing (baseline) and between 5 to 30 min after dosing using Chart program (v5.5.4, AD Instruments), and calculated the ratio to baseline.
Cystometry in rat acetic acid-induced hyper -reflexia model
Female Sprague-Dawley rats weighed 250-350 g were housed in a temperature- and light (12-h light/dark cycle)-controlled room, and were allowed access to food and water ad libitum. The animals were anesthetized with urethane (1.0 g/kg, i.p.). Supplemental urethane was given if necessarily. A lower abdominal midline incision was made to expose the bladder, and a polyethylene catheter (PE-50) was inserted into the bladder dome for recording the intravesical pressure and intravesical infusion at the rate of 0.05 ml/min. The intravesical pressure was measured using a pressure transducer, and signal was recorded using a multiple channel data acquisition system (Power lab, AD Instruments, Biopac systems, Colorado Springs, CO) at a sampling rate of 10 Hz. After confirming stable inter-micturtion interval and micturition pressure by intravesical infusion of saline, 0.25% of acetic acid-saline solution was infused at the same infusion rate. After 30-60 min, drugs were intravenously infused using infusion pumps at a rate of 10 μl/min. Intermicturition interval (functional bladder capacity) and micturition pressure (maximum intravesical pressure) were obtained from micturitions prior to dosing (baseline) and between 30 to 45 min after starting drug infusion using Chart program (v5.5.4, AD Instruments), and calculated the ratio to baseline.
Generation of a Human P2X$ and P2X2/3 Stable Cell Line - Human P2X3 receptor cDNA (Accession number NM_002559) was subcloned as a 5'XhoI and 3'HindIII fragment into the expression vector pcDNA5/FRT (Invitrogen). Human P2X2 receptor cDNA (Accession number NM l 74873) was subcloned as a 5ΕcoRI and 3'NotI fragment into the expression vector pIRESneo2 (BD Biosciences Clontech). The human P2X3 expression construct was transfected using Lipofectamine 2000 (Invitrogen) into Flp-in - 293 cells (Invitrogen) according to the manufacturer's directions. Cells positive for flp-mediated recombination of rhesus P2X3 were selected using 150 μg/ml hygromycin. The stable human P2X3 cell line was co-transfected with the human P2X2 expression construct using Lipofectamine 2000 as above and co-transfected cells selected using 100 mg/ml hygromycin and 1 mg/ml G418. The stable P2X3 cell line was propagated in DMEM, 10% FBS, 100 μg/ml hygromycin, and 100 units/ml penicillin and 100 μg/ml streptomycin, and maintained at 37 ° and 95% humidity. The stable P2X2/3 cell line was propagated as above with the addition of 500 μg/ml G418.
Intracellular Calcium Measurement to Assess Antagonist Affinity — A fluorescent imaging plate reader (FLIPR; Molecular Devices) was used to monitor intracellular calcium levels using the calcium-chelating dye Fluo-4 (Molecular Probes). The excitation and emission wavelengths used to monitor fluorescence were 488 run and 530 nm, respectively. Cells expressing either human P2X3 or human P2X2/3 were plated at a density of 20,000 cells/well (20 μl/well) in 384- well black- walled plates approximately 20 hours before beginning the assay. On the day of the assay 20 μl of loading buffer (Hank's balanced salt solution, 2.5 mM CaCl2, 20 mM HEPES, 0.1% BSA, 2.5 mM probenecid, TR-40, Fluo-4, and 138 mM NMDG substituted for NaCl) is added and cells dye-loaded for 60 min in the dark at room temperature. Ten minutes prior to adding agonist, the antagonist was added in a volume of 10 μl and allowed to incubate at room temperature. During this period fluorescence data is collected at 3 sec intervals followed by 10 sec intervals. The agonist, α,β-meATP, is added at a 6x concentration ([α,β-meATP]finai = EC50). Following agonist addition fluorescence was measured at 5 sec intervals and analyzed based on the increase in peak relative fluorescence units (RFU) compared to the basal fluorescence. Peak fluorescence was used to determine the inhibitory effect at each concentration of antagonist by the following equation:
% Inhibition = 100 * (1 - ((RFU(drug) - RFU(controi)) / (RFU(DMso only) - RFlWoi))))
In vitro Electrophysiological Assay — Cells expressing human P2X3 receptors were grown to a confluence of 65-85% 20 to 32 hours prior to assay. The cells were dissociated with trypsin, centrifuged, and resuspended in bath solution at a cell density of 1x106 cells/ml and loaded onto
PatchXpress. The bath solution contained 150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1.2 mM
MgCl2, 10 mM HEPES, and 11.1 mM glucose, at pH 7.2. The intracellular solution contained either 140 mM K-aspartate, 20 mM NaCl, 5 mM HEPES, 10 mM EGTA, at pH 7.2 or 30 mM CsCl, 5 mM HEPES, 10 mM EGTA, 120 mM CsF, 5 mM NaF, 2 mM MgC12, pH=7.3 with
CsOH. Agonist stock solutions were prepared in H2O and diluted in bath solution prior to use.
All antagonists were prepared as 10 mM stock solutions in DMSO and diluted in bath solution prior to use. All experiments were performed on cells under the whole-cell patch clamp configuration at room temperature. Up to 16 individual cells could be patch clamped simultaneously on the PatchXpress instrument. A baseline response was established by repeated CTP (100 μM; for 2 sec.) followed by antagonist incubation for 2 min. in the absence of CTP. After antagonist preincubation 100 μM CTP and antagonist were co-administered to determine the inhibitory effect of the antagonist. These steps were then repeated on the same cell with a range of concentrations of the antagonist. A maximum of five concentrations of antagonist were tested on any individual cell. The control P2X3 current amplitude (Ip2χ3-(Controi)) was taken as an average of the peak current amplitude from the last two agonist additions prior to incubation with an antagonist. The peak P2X3 current amplitude in the presence of an antagonist (Ip2X3-(CIrUg)) was used to calculate the inhibitory effect at each concentration of the antagonist according to the following equation:
% inhibition of P2X3 =100*(Ip2χ3-(COntrol)-Ip2X3-(drug))/Ip2X3-(controI)
Each concentration of an antagonist was tested on at least two independent cells. The concentration of drug required to inhibit P2X3 current by 50% (IC50) was determined by fitting of the Hill equation to the averaged % inhibition data at each concentration:
% of Control =100 • (1 + ([Drug]/IC50) p )A
In vitro Electrophysiological Assay for P 2X2/3 - P2X2/3 was assayed as above with two protocol modifications: 1) 30 μM α,β-meATP used as agonist; and 2) current amplitude was measured at the end of 2-second agonist application. Using the assays described herein the compounds of this invention were found to be active for the P2X3 receptor. The compounds of formula I have an IC5o activity of 100 μM or less for the P2X3 receptor. Many of the compounds of formula I have an IC50 of less than 200 πM.
For example, the compounds below have an IC50 of 200 nM or less in the "Intracellular Calcium Measurement to Assess Antagonist Affinity" assay:
St
Figure imgf000087_0001
3-(5-chloropyridin-2-yl)-N- 110
[( 1 R)- 1 -(5-fluoropyridin-2- yl)ethyl]-5-[(5S)-5-pyridin-2- yl-4,5 -dihydroisoxazol-3 - yljbenzamide
N-[(lR)-l-(5-fluoropyridin- 20
2-yl)ethyl]-3-(5- methylpyridin-2-yl)-5-[(5S)-
5-pyridin-2-yl-4,5-
Figure imgf000087_0002
dihydroisoxazol-3 - yljbenzamide
10
Figure imgf000087_0003

Claims

WHAT IS CLAIMED:
1. A compound of structural formula I:
Figure imgf000088_0001
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein: X and Y independently represent N, or CRl;
A represents a five membered heterocyclyl selected from the group consisting of (CH2)nθxazolyl, (CH2)nisoxazolyl, (CH2)ndihydro-isoxazolyl, and (CH2)nθxadiazolyl;
Rl represents H, Ci-6 alkyl, halogen, (CH2)nCF3, Cβ-io cycloalkyl, CN, (CH2)nOR2, (CH2)nC5-10 heterocyclyl, (CH2)nC6-10 aryl, or Ci_6 alkoxy; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ci -6 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN;
R2 represents H, Ci -6 alkyl;
R3 represents CR2R4R5;
or R2 and R3 can be combined with the nitrogen to which they are attached to form a C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra;
R4 and R5 independently represent H, (CH2)nOR2, CHF2, (CH2)nC5-l0 heterocyclyl, (CH2)nC6-10 aryl, C3.10 cycloalkyl, Ci-6 alkoxy, or Ci_6 alkyl; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ra;
R6 and R7 independently represent hydrogen, Cl -6 alkyl, halogen, hydroxyl, (CH2)nCF3, C3-6 cycloalkyl, (CH2)nC5-io heterocyclyl, or (CH2)nC6-10 aryl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of C 1-6 alkyl, C5-10 heterocyclyl, halogen, (CH2)nOR2, - C(R2)2OR -C(O)R2, (CH2)nCF3,or CN; or Re and R7 can be combined with a carbon atom on the ring to form a 4 to 6 membered spirocycle;
Ra represents Ci-6 alkyl, halogen, -OR2, hydroxyl, (CH2)nCF3, -O-, C3.6 cycloalkyl, C5-10 heterocyclyl, or Cβ-lO aryl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of C 1-6 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN; and
n represents 0 to 4.
2. The compound according to claim 1 wherein X is N and Y is CH.
3. The compound according to claim 1 wherein A is isoxazolyl, dihydro- isoxazolyl, or oxazolyl.
4. The compound according to claim 3 wherein A is isoxazolyl.
5. The compound according to claim 3 wherein A is dihydro-isoxazolyl.
6. The compound according to claim 3 wherein A is oxazolyl.
7. The compound according to claim 1 wherein the R2 in R3 is hydrogen and R4 and R5 are both Cl -6 alkyl or one of R4 and R5 is Ci -6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocylyl optionally substituted with 1 to 3 groups of Ra.
8. The compound according to claim 1 wherein one of Rβ and R7 is hydrogen and the other is C6-K) aryl, or C5-IO heterocyclyl optionally substituted with 1 to 3 groups of Ra.
9. The compound according to claim 1 represented by formula II:
Figure imgf000089_0001
II or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein A is isoxazolyl, dihydro-isoxazolyl, or oxazolyl.
10. The compound according to claim 9 wherein A is isoxazolyl, one of R6 and R7 is hydrogen and the other is C6-K) aryl, or C5-IO heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is nitrogen, R3 is CHR4R5; and one of R4 and R5 is C 1-6 alkyl and the other is Cβ-lO aryl, or C5-10 heterocyclyl, said aryl and heterocylyl optionally substituted with 1 to 3 groups of Ra.
11. The compound according to claim 9 wherein A is dihydro-isoxazolyl, one of Re and R7 is hydrogen and the other is Cβ-lO aryU or C5.10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is nitrogen, R3 is CHR4R5, and one of R4 and R5 is Cl -6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocylyl optionally substituted with 1 to 3 groups of Ra.
12. The compound according to claim 9 wherein A is oxazolyl, one of R^ and R7 is hydrogen and the other is C6-10 aryl, or C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, X is nitrogen, R3 is CHR4R5, and one of R4 and R5 is Cl -6 alkyl and the other is C6-10 aryl, or C5-10 heterocyclyl, said aryl and heterocylyl optionally substituted with 1 to 3 groups of Ra.
13. The compound according to claims 10, 11, or 12 where is A is selected from the group consisting of:
Figure imgf000090_0001
14. The compound according to claim 1 wherein A is
Figure imgf000090_0002
15. A compound of Table 1 : Table 1
Figure imgf000090_0003
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
- Ill -
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
16. A compound according to claim 15 which is: N-[(lR)-l-(5-fluoro-l-oxidopyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-
4,5-dihydroisoxazol-3-yl]benzamide;
3 -(5 -methylpyridin-2-yl)-N- { ( 1 R)- 1 - [ 1 -oxido-6-(trifluoromethyl)pyridin-3 -yl] ethyl } -5 - [(5 S)-5 - pyridin-2-yl-4,5-dihydroisoxazol-3-yl]benzamide; 4'-methyl-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7-yl)-N-[(lR)-l-(4H-l,2,4-triazol-3- yl)ethyl]biphenyl-3 -carboxamide;
N-[(lR)-l-(3,5-difluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-(5-oxa-6-azaspiro[3.4]oct-
6-en-7-yl)benzamide;
2'-fluoro-4'-methyl-5-[(5S)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]-N-[(lR)-l-(4H-l,2,4- triazol-3-yl)ethyl]biphenyl-3-carboxamide;
N-[(3,5-difluoropyridin-2-yl)methyl]-3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzamide;
3-(5-chloropyridin-2-yl)-N-[(lR)-l-(5-fluoropyridin-2-yl)ethyl]-5-[(5S)-5-pyridin-2-yl-4,5- dihydroisoxazol-3 -yl] benzamide ; N-[(lR)-l-(5-fluoropyridin-2-yl)ethyl]-3-(5-hydroxy-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl)-5-
(5 -methylpyridin-2-yl)benzamide ;
N-[(lR)-l-(5-fluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzamide;
3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]-N-{(lR)-l-[6- (trifluoromethyl)pyridin-3 -yl] ethyl } benzamide ;
N-[(lR)-l-(5-fluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-[(5R)-5-pyridin-2-yl-4,5- dihydroisoxazol-3-yl]benzamide;
3-(5-methylpyridin-2-yl)-5-[(5R)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]-N-{(lR)-l-[6-
(trifluoromethyl)pyridin-3 -yl] ethyl } benzamide; 3 -(5-methylpyridin-2-yl)-5-( 1 ,3 -oxazol-2-yl)-N- { ( 1 R)- 1 -[ 1 -oxido-6-(trifluoromethyl)pyridin-3 - yl] ethyl } benzamide;
N- [( 1 R)- 1 -(3 -methyl- 1 ,2,4-oxadiazol-5 -yl)ethyl] -3 -(5-methylpyridin-2-yl)-5 -( 1 ,3 -oxazol-2- yl)benzamide; or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
17. A compound according to claim 16 which is N-[(lR)-l-(3,5- difluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)-5-(5-oxa-6-azaspiro[3.4]oct-6-en-7- yl)benzamide or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
18. A compound according to claim 16 which is 3-(5-chloropyridin-2-yl)-N- [( 1 R)- 1 -(5-fluoropyridin-2-yl)ethyl] -5 - [(5 S)-5 -pyridin-2-yl-4,5 -dihydroisoxazol-3 -yl]benzamide or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
19. A compound according to claim 16 which is N-[(lR)-l-(5-fluoropyridin-2- yl)ethyl]-3-(5-methylpyridin-2-yl)-5-[(5S)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]benzamide pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
20. A compound according to claim 16 which is 3-(5-methylpyridin-2-yl)-5- [(5S)-5-pyridin-2-yl-4,5-dihydroisoxazol-3-yl]-N-{(lR)-l-[6-(trifluoromethyl)pyridin-3- yl] ethyl }benzamide or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
21. A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to Claim 1.
22. A method for treating or preventing chronic or acute pain, treating or controlling epilepsy, or enhancing the quality of sleep in a mammalian patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound according to formula I in claim 1 or a pharmaceutically acceptable salt thereof.
23. The method according to claim 17 further comprising one or more therapeutically active compounds selected from the group consisting of opiate agonists or antagonists, calcium channel antagonists, 5HT, 5-HTIA complete or partial receptor agonists or antagonists , sodium channel antagonists, N-methyl-D-aspartate (NMDA) receptor agonists or antagonists, COX-2 selective inhibitors, neurokinin receptor 1 (NKl) antagonists, non-steroidal anti-inflammatory drugs (NSAID), selective serotonin reuptake inhibitors (SSRI) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), tricyclic antidepressant drugs, norepinephrine modulators, lithium, valproate, norepinephrine reuptake inhibitors, monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), alpha- adrenoreceptor antagonists, atypical anti-depressants, benzodiazepines, corticotropin releasing factor (CRF) antagonists, neurontin (gabapentin) and pregabalin
PCT/US2008/012271 2007-10-31 2008-10-29 P2x3 receptor antagonists for treatment of pain WO2009058299A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP08844889.9A EP2215048B1 (en) 2007-10-31 2008-10-29 P2x3 receptor antagonists for treatment of pain
US12/740,098 US8461185B2 (en) 2007-10-31 2008-10-29 P2X3 receptor antagonists for treatment of pain
AU2008319309A AU2008319309B2 (en) 2007-10-31 2008-10-29 P2X3 receptor antagonists for treatment of pain
ES08844889.9T ES2553412T3 (en) 2007-10-31 2008-10-29 P2X3 receptor antagonists for pain management
JP2010532049A JP5552430B2 (en) 2007-10-31 2008-10-29 P2X3 receptor antagonist for the treatment of pain
CA2703915A CA2703915C (en) 2007-10-31 2008-10-29 P2x3 receptor antagonists for treatment of pain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US137507P 2007-10-31 2007-10-31
US61/001,375 2007-10-31
US13217808P 2008-06-16 2008-06-16
US61/132,178 2008-06-16

Publications (1)

Publication Number Publication Date
WO2009058299A1 true WO2009058299A1 (en) 2009-05-07

Family

ID=40591358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/012271 WO2009058299A1 (en) 2007-10-31 2008-10-29 P2x3 receptor antagonists for treatment of pain

Country Status (7)

Country Link
US (1) US8461185B2 (en)
EP (1) EP2215048B1 (en)
JP (1) JP5552430B2 (en)
AU (1) AU2008319309B2 (en)
CA (1) CA2703915C (en)
ES (1) ES2553412T3 (en)
WO (1) WO2009058299A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137351A1 (en) * 2009-05-29 2010-12-02 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2010149634A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists
WO2010149541A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel oxazolone and pyrrolidinone-substituted arylamides
JP2011051977A (en) * 2009-08-03 2011-03-17 Nissan Chem Ind Ltd Optically-active substance and diastereomer salt of dihydroisoxazole-substituted benzoic acid compound, and method for producing the same
WO2012053186A1 (en) * 2010-10-18 2012-04-26 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
US8946439B2 (en) 2008-02-29 2015-02-03 Evotec Ag Amide compounds, compositions and uses thereof
US9029409B2 (en) 2011-04-30 2015-05-12 Abbvie Inc. Isoxazolines as therapeutic agents
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
US9133122B2 (en) 2008-09-18 2015-09-15 Evotec Ag Amide compounds, compositions and uses thereof
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
CN108164457A (en) * 2013-01-31 2018-06-15 沃泰克斯药物股份有限公司 Pyridine keto-amide as sodium channel modulators
US10174016B2 (en) 2014-12-09 2019-01-08 Beyer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US10183937B2 (en) 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US10568876B2 (en) 2014-09-05 2020-02-25 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US10947222B2 (en) 2016-11-18 2021-03-16 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US11104690B2 (en) 2016-11-18 2021-08-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
CN114644622A (en) * 2020-12-17 2022-06-21 山东省联合农药工业有限公司 Isoxazoline-containing pyridine biphenyl compound and preparation method and application thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004570A (en) * 2008-10-31 2011-06-17 Merck Sharp & Dohme P2x3, receptor antagonists for treatment of pain.
JP2012521429A (en) 2009-03-23 2012-09-13 メルク・シャープ・エンド・ドーム・コーポレイション P2X3 receptor antagonist for the treatment of pain
EP2410857B1 (en) 2009-03-23 2014-01-29 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
WO2010111059A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
SG177308A1 (en) 2009-06-22 2012-02-28 Hoffmann La Roche Novel biphenyl and phenyl-pyridine amides
WO2018159787A1 (en) * 2017-03-01 2018-09-07 国立大学法人北海道大学 Production method for disease model non-human animal, disease model non-human animal, drug screening method using disease model non-human animal, and disease risk determination method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029920A1 (en) * 2002-08-06 2004-02-12 Kuduk Scott D. 2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives
WO2004069805A1 (en) * 2003-02-10 2004-08-19 Bayer Healthcare Ag Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists
WO2005073193A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20070037974A1 (en) * 2005-08-15 2007-02-15 Roche Palo Alto Llc Inhibitors of P2X3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6829356B1 (en) 1999-06-29 2004-12-07 Verisign, Inc. Server-assisted regeneration of a strong secret from a weak secret
EP1740559B1 (en) * 2004-04-20 2014-10-15 Merck Sharp & Dohme Corp. 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007010553A2 (en) 2005-03-24 2007-01-25 Arrow Coated Products Ltd Combined multi-layered water soluble film and process for producing the same
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
WO2007001973A1 (en) 2005-06-28 2007-01-04 Astrazeneca Ab New use
WO2007041087A2 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Nucleic acids encoding a functional mammalian purinoreceptor, p2x3, methods of production and use thereof
CA2654915C (en) 2006-06-29 2015-07-28 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
AU2007297627A1 (en) * 2006-09-21 2008-03-27 Merck Sharp & Dohme Corp. Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease
JP5084839B2 (en) * 2006-11-09 2012-11-28 エフ．ホフマン−ラ ロシュ アーゲー Thiazole and oxazole substituted arylamides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029920A1 (en) * 2002-08-06 2004-02-12 Kuduk Scott D. 2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives
WO2004069805A1 (en) * 2003-02-10 2004-08-19 Bayer Healthcare Ag Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists
WO2005073193A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20070037974A1 (en) * 2005-08-15 2007-02-15 Roche Palo Alto Llc Inhibitors of P2X3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2215048A4 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946439B2 (en) 2008-02-29 2015-02-03 Evotec Ag Amide compounds, compositions and uses thereof
US9133122B2 (en) 2008-09-18 2015-09-15 Evotec Ag Amide compounds, compositions and uses thereof
JP2012528078A (en) * 2009-05-29 2012-11-12 ラクオリア創薬株式会社 Aryl-substituted carboxamide derivatives as calcium channel blockers or sodium channel blockers
US9522140B2 (en) 2009-05-29 2016-12-20 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2010137351A1 (en) * 2009-05-29 2010-12-02 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
US9101616B2 (en) 2009-05-29 2015-08-11 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
CN102448937A (en) * 2009-05-29 2012-05-09 拉夸里亚创药株式会社 Aryl Substituted Carboxamide Derivatives As Calcium Or Sodium Channel Blockers
JP2012530748A (en) * 2009-06-22 2012-12-06 エフ．ホフマン−ラ ロシュ アーゲー Novel oxazolone and pyrrolidinone substituted arylamides
CN102803245A (en) * 2009-06-22 2012-11-28 弗·哈夫曼-拉罗切有限公司 Novel Indole, Indazole And Benzimidazole Arylamides As P2X3 And/or P2X2/3 Antagonists
CN102438989A (en) * 2009-06-22 2012-05-02 霍夫曼-拉罗奇有限公司 Novel oxazolone and pyrrolidinone-substituted arylamides
JP2014111618A (en) * 2009-06-22 2014-06-19 F. Hoffmann-La Roche Ag Novel oxazolone and pyrrolidinone-substituted arylamide
WO2010149541A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel oxazolone and pyrrolidinone-substituted arylamides
CN102803245B (en) * 2009-06-22 2015-02-11 弗·哈夫曼-拉罗切有限公司 Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists
WO2010149634A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists
JP2011051977A (en) * 2009-08-03 2011-03-17 Nissan Chem Ind Ltd Optically-active substance and diastereomer salt of dihydroisoxazole-substituted benzoic acid compound, and method for producing the same
CN106478497A (en) * 2010-10-18 2017-03-08 拉夸里亚创药株式会社 Aryl amine derivatives as TTX S blocker
US9302991B2 (en) 2010-10-18 2016-04-05 Raqualia Pharma Inc. Arylamide derivatives as TTX-S blockers
JP2014177450A (en) * 2010-10-18 2014-09-25 Raqualia Pharma Inc Arylamide derivatives as ttx-s blockers
WO2012053186A1 (en) * 2010-10-18 2012-04-26 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
CN106478497B (en) * 2010-10-18 2020-05-08 拉夸里亚创药株式会社 Arylamine derivatives as TTX-S blockers
US9029409B2 (en) 2011-04-30 2015-05-12 Abbvie Inc. Isoxazolines as therapeutic agents
CN108164457A (en) * 2013-01-31 2018-06-15 沃泰克斯药物股份有限公司 Pyridine keto-amide as sodium channel modulators
US11673864B2 (en) 2013-01-31 2023-06-13 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
CN108164457B (en) * 2013-01-31 2021-07-09 沃泰克斯药物股份有限公司 Pyridone amides as sodium channel modulators
US9718812B2 (en) 2014-02-05 2017-08-01 Axxam S.P.A. Substituted thiazole or oxazole P2X7 receptor antagonists
US10167281B2 (en) 2014-02-05 2019-01-01 Axxam S.P.A. Substituted thiazole or oxazole P2X7 receptor antagonists
WO2015118019A1 (en) * 2014-02-05 2015-08-13 Axxam S.P.A. Substituted thiazole or oxazole p2x7 receptor antagonists
CN106103432A (en) * 2014-02-05 2016-11-09 阿克萨姆股份公司 The thiazole being replaced or azoles P2X7 receptor antagonist
CN106103432B (en) * 2014-02-05 2019-10-18 阿克萨姆股份公司 Substituted thiazole or oxazole P2X7 receptor antagonist
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
US10568876B2 (en) 2014-09-05 2020-02-25 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US10183937B2 (en) 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
EP3587417A1 (en) 2014-12-09 2020-01-01 Bayer AG 1,3-thiazol-2-yl substituted benzamides
US10472354B2 (en) 2014-12-09 2019-11-12 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US10202369B2 (en) 2014-12-09 2019-02-12 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US11142523B2 (en) 2014-12-09 2021-10-12 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US10174016B2 (en) 2014-12-09 2019-01-08 Beyer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US10947222B2 (en) 2016-11-18 2021-03-16 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US11104690B2 (en) 2016-11-18 2021-08-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
CN114644622A (en) * 2020-12-17 2022-06-21 山东省联合农药工业有限公司 Isoxazoline-containing pyridine biphenyl compound and preparation method and application thereof
WO2022127564A1 (en) * 2020-12-17 2022-06-23 山东省联合农药工业有限公司 Isoxazoline-containing pyridine biphenyl compounds, preparation method therefor and use thereof
CN114644622B (en) * 2020-12-17 2022-10-18 山东省联合农药工业有限公司 Isoxazoline-containing pyridine biphenyl compound and preparation method and application thereof

Also Published As

Publication number Publication date
EP2215048B1 (en) 2015-10-28
EP2215048A1 (en) 2010-08-11
ES2553412T3 (en) 2015-12-09
EP2215048A4 (en) 2010-12-01
CA2703915C (en) 2015-02-24
AU2008319309B2 (en) 2012-09-06
US20110003822A1 (en) 2011-01-06
JP2011502149A (en) 2011-01-20
AU2008319309A1 (en) 2009-05-07
US8461185B2 (en) 2013-06-11
JP5552430B2 (en) 2014-07-16
CA2703915A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
EP2215048B1 (en) P2x3 receptor antagonists for treatment of pain
EP2215049B1 (en) P2x3, receptor antagonists for treatment of pain
EP2410858B1 (en) P2x3 receptor antagonists for treatment of pain
EP2358371B1 (en) P2x3, receptor antagonists for treatment of pain
EP2411001B1 (en) P2x3, receptor antagonists for treatment of pain
EP2410857B1 (en) P2x3, receptor antagonists for treatment of pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08844889

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008319309

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2703915

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010532049

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008844889

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008319309

Country of ref document: AU

Date of ref document: 20081029

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12740098

Country of ref document: US